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ABSTRACT 
 
Bayesian approaches to the design and analysis of clinical trials and health-care 
evaluation studies are becoming popular. Compared to frequentist methods, the Bayesian 
approach offers a flexible way to incorporate all sources of information into an analysis, 
including both preexisting knowledge as well as new information and evidence as it occurs. 
Bayesian methods have been shown to be more efficient when using appropriate informative 
priors, and have been used in various clinical studies and health-care evaluation studies. In this 
dissertation, we have developed Bayesian models and applied these models to two specific 
problems: (1) the development and assessment of patient reported outcomes and (2) the 
prediction of patient accrual in clinical trials. Bayesian Instrument Development (BID) is 
introduced to examine patient reported outcomes. The stability of BID is evaluated using 
simulation study, and user-friendly BID software is also proposed. The BID software can 
provide Bayesian estimates of content and construct analysis for developing patient reported 
outcome measures. Also, we developed and tested Bayesian models and applied them to patient 
accrual monitoring in clinical trials. Specifically, two hierarchical priors are introduced, and the 
properties of different priors are evaluated using data from clinical studies and simulations. User-
friendly software for accrual monitoring is described and details for its use are provided. The 
accrual software is used to predict the accrual at the end of a clinical trial given accrual to the 
present time, and can provide the probability that the trial will finish within the planned time 
frame or the time frame required to recruit the planned number of subjects.  The dissertation 
concludes with summary and future studies.  
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Reverend Thomas Bayes first proposed a theorem to update beliefs that later became 
known as his ‘rule’ in the 1740s, though the result was not published until two years after his 
death (Bayes, 1763).  In the 2½ centuries since, Bayesian statistics has evolved from 
controversial to widely used for solving real-world problems in politics, economics, engineering, 
and the basic and biomedical sciences. For example, Turing applied Bayes’ rule to break the 
German cipher Enigma and locate U-boats during World War II (McGrayne, 2011).  More 
recently, Stone et al. (2014) used a Bayesian approach to locate the debris of Air France Flight 
447 which crashed in the Atlantic Ocean on June 1st, 2009. Beginning with the rapid 
development of computational tools in the 1980s, Bayesian methods have become an 
increasingly popular and widely accepted approach to statistics. Thus, it is not surprising that 
healthcare research also has benefited from Bayes’ rule. 
Bayesian approaches to the design and analysis of clinical trials and health-care 
evaluation studies are becoming popular (Berry, 2004).  Compared to frequentist methods, the 
Bayesian approach offers a flexible way to incorporate all sources of information into an 
analysis, including both preexisting knowledge (e.g., historical information, researchers’ 
previous experience) as well as new information and evidence as it occurs (Spiegelhalter, 
Abrams & Myles, 2004). Bayesian methods have been shown to be more efficient when using 
appropriate informative priors (Samaniego & Reneau, 1994), and have been used in various 
clinical studies and health-care evaluation studies (Berry, 2004).  
Bayesian methods, like frequentist methods, require a data model (or likelihood), 
  ,f y where y represents observable quantities (e.g., experimental data) and θ denotes 
unobservable model parameters.  Relevant prior information about θ is incorporated into the 
analysis by means of a prior probability distribution, represented by    . Information about 
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θ is subsequently updated by the data generated from the current experiment through the 
likelihood,  f y . This updated knowledge about θ  is represented by the posterior 
probability distribution,    y , where Bayes’ theorem establishes the relationship 
between the prior and posterior information: 
 
   
   
|
| ,
|
f
f d
  
 
   



y
y
y
 
where  denotes the parameter space (Casella and Berger, 2002). Specification of prior 
distributions, model assessment, and use in practice are key elements of Bayesian statistical 
analysis that will be addressed in the following sections.  
1. Bayesian prior distributions 
 In general, Bayesian prior distributions can be categorized as non-informative or 
informative based on the amount of information they provide about θ relative to the information 
provided through the data likelihood. Non-informative priors—sometimes referred to as 
reference or flat priors (Gelman et al., 2013)—are generally uniform over the range of values for 
θ  that are of interest. Uniform densities, by definition, provide little information about θ  aside 
from a range of possible values, thus allowing the data to calibrate the posterior distribution over 
the most likely values of θ  through the likelihood. Therefore, non-informative priors provide 
data-driven analyses and the results obtained from such approaches are very similar to those 
from corresponding frequentist methods.  
 Unlike non-informative prior distributions, informative priors incorporate into an analysis 
preexisting knowledge or expert beliefs about the most likely values of θ . Eliciting expert 
beliefs and translating them into a prior distribution in mathematical terms is challenging and 
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considered to be the most important step in Bayesian statistics   (Spiegelhalter, Abrams & Myles, 
2004). Common approaches of prior elicitation have been summarized and discussed by many 
researchers (e.g., Spiegelhalter, Abrams & Myles, 2004; Johnson et al., 2010; O’Hagan et al., 
2006). According to Spiegelhalter, Abrams & Myles (2004), the different approaches can be 
divided into: (a) informal discussion, (b) structural interviewing and formal pooling of opinion, 
(c) structured questionnaires, and (d) computer-based elicitation. Through these approaches, 
various priors have been identified and are commonly applied in Bayesian analyses 
(Spiegelhalter, Abrams & Myles, 2004). As prior beliefs of experts come from different 
expectations, informative priors can be either “pessimistic” or “optimistic” (Spiegelhalter, 
Abrams & Myles, 2004; Cook, Jairo, & Pericchi, 2011).  Pessimistic priors reflect a skeptical 
position and usually are centered over values of θ  with high probability of corresponding to the 
null hypothesis. Optimistic priors relate to more positive expectations and correspond with 
values of θ  that reflect the hypothesis an investigator wishes to support through 
experimentation. 
 Because of the subjective nature of informative priors based on expert opinion, there have 
been many criticisms of the prior eliciting process. One of the criticisms is that experts could be 
biased in their beliefs. Studies have shown that many investigators tend to overestimate the 
strength of their prior beliefs; that is, expert opinion tends to be overly “optimistic” (O’Hagan et 
al., 2006). For example, it was shown by Hughes that clinicians tend to expect that a new therapy 
/drug to be a benefit in a clinic trial study. Therefore their prior brief on the new therapy  usually 
is exaggerated (Hughes, 1991). The bias of prior elicitation also may come from the choice of 
experts and/or time of elicitation (Kadane & Wolfson, 1998). When priors are miscalibrated, 
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Bayesian estimates may lose their superiority to other estimation methods and should be 
processed with caution (Samaniego & Reneau, 1994).   
 To overcome the concerns associated with expert-based informative priors, methods have 
been proposed to incorporate historical information effectively and less subjectively (Berger, 
2006; Ghosh, 2011).  Power priors (Ibrahim & Chen, 2000) are one such method that avoids 
many of the difficulties and criticisms in prior elicitation by permitting prior parameters to be 
determined directly from historical information. Because the original form of the approach 
violated the likelihood principle, a modified power prior was proposed by several groups of 
researchers (Duan, Ye, & Smith, 2006; Neuenschwander, Branson, & Spiegelhalter, 2009): 
𝜋(𝜃, 𝑎0|𝐷0) = 𝐶(𝑎0) 𝐿(𝜃|𝐷0)
𝑎0𝜋0(𝜃)𝜋(𝑎0).  
Specifically, the modified power prior contains two parameters: historical information, 𝐷0, and a 
weight parameter, 𝑎0. The borrowing of strength from the historical information is controlled by 
raising the likelihood of 𝐷0,  𝐿(𝜃|𝐷0), to a power, 𝑎0, representing the relative importance of the 
historical information to the Bayesian analysis. This weight parameter is typically restricted to 
values between zero and one, with 𝑎0 = 1 corresponding to the usual updating associated with 
Bayes’ theorem.  As 𝑎0 approaches zero, the impact of the historical information on the power 
prior distribution diminishes.  
 Another way to utilize historical data objectively is through the commensurate power 
prior, which is proposed by Hobbs et al. (2011). The commensurate prior assumes different 
parameters represent historical ( 0θ ) and current (θ ) information. The precision, τ , of θ  
conditioned on 0θ  parameterizes the commensurability (correspondence) between the two 
sources of information. For example, when evidence for the commensurability is weak, τ will be 
small and the conditional prior variance of θ  will be increased. On the contrary, when the 
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current and historical data are similar, the commensurability is strong and the precision will be 
large.  
 The idea of objective priors in Bayesian statistics has been debated (Goldstein, 2006; 
Berger, 2006; Kadane, 2006). They are not recognized as “fully Bayesian” by some Bayesian 
statisticians and it is advised that the priors should be used with caution. In all cases, researchers 
should evaluate the appropriateness of the model (Kadane, 2006; Press, 2009). As stated by 
Spiegelhalter, Abrams, & Myles (2004), there is no concept of a “correct” prior distribution—the 
properties of different priors could be different under varying situations. Therefore, model 
evaluation is critical in guiding and assessing the impact of prior specifications.  
2. Model Evaluation  
 By definition, statistics is the science of decision-making in the presence of uncertainty. 
Due to the inherent uncertainty in measurements taken from samples it is near impossible to 
obtain a perfect statistical model. In general, statistical models are known to be imperfect; 
therefore, it is important to compare competing models. An ideal statistical model would be 
simple, yet representative and useful in real situations. 
 Statistical models can be evaluated using real data or via simulation studies.  Mean 
squared error (MSE) is a frequentist criteria for model evaluation that represents the squared 
difference between an estimator and its target that can be used to identify which of a set of 
candidate models best fits the data. A model or method is shown to be superior if it provides 
smaller mean square error. MSE incorporates both the variance and bias of an estimator. To 
illustrate, suppose the hits on a target (the true value of a parameter) represent the model building 
process to estimate a parameter, with each hit symbolizing an individual realization of the model 
system. Figure 1-1 displays the different realizations for four different scenarios in the form of 
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scatter plots. It always is ideal to find an unbiased estimator with low variance (Figure 1-1A). 
However, the unbiased estimator does not guarantee an efficient estimator; that is, an estimator 
that requires fewer samples to achieve a prespecified level of precision (Figure 1-1B). 
Alternatively, an estimator will be superior if it has negligible bias but smaller variance (Figure 
1C).  In this way, MSE incorporates both the degree of variation and the degree of bias in an 
estimator to assess its quality. 
 Evaluation of the Bayesian approach and comparisons to frequentist alternatives have 
been studied extensively (Chaloner, 1987; Samaniego & Reneau, 1994; Browne & Drapper, 
2006; Neath & Langenfeld, 2012). It was first shown theoretically and empirically by Samaniego 
& Reneau (1994) that Bayesian estimates are better than a likelihood approach when the priors 
are calibrated closely enough to the truth. When a small bias exists, Bayesian methods still 
outperform frequentist methods if the data has a paradoxically large variance. When prior 
distributions are highly miscalibrated, Bayesian methods will no longer be superior to other 
methods.  As previously discussed, prior specification is very important in a Bayesian approach. 
Therefore, it is also critical to do model comparisons between Bayesian methods for different 
prior specifications. An ideal prior setting would be robust and work well under varying 
conditions.  
3. Software  
 It is the significant improvement of computational techniques that spurred the rapid 
development of Bayesian statistics and its increased use in different fields, especially in areas of 
the design and operations of clinical trials and health-care evaluation. With the availability of 
high speed computers, Bayesian analysis can be constructed, validated, and used in practice. 
There are several software packages and languages that can be used. For general computing, 
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statisticians write their own Bayesian algorithms using a lower level language, such as 
FORTRAN and C++ (Eubank & Kupresanin 2011). Some functional languages, such as R, 
MATLAB, Phyton are very popular and used a lot by statisticians (Rashed et al., 2012; Albert, 
2007). WinBUGS (Lunn et al., 2000; Lunn et al., 2009), OpenBUGS (Spiegelhalter, et al., 2007), 
JAGS (Plummer, 2003) and STAN (Stan Development Team, 2014) are higher level functional 
languages specific for Bayesian analysis using Markov chain Monte Carlo (MCMC) methods 
and/or other optimization algorithms. SAS has some Bayesian options within its procedures but 
requires users with in-depth knowledge of statistical computing in SAS (Sullivan & Greenland, 
2013). SAS also is not very flexible for implementing new and innovative approaches. Other 
well-known graphical user interface (GUI) statistical software (e.g., SPSS and JMP) do not have 
Bayesian capabilities. In general, Bayesian statistical software is limited, especially for clinical 
researchers.  
 For most clinical researchers, it is not practical to implement a Bayesian analysis using a 
functional language, such as R and WinBUGS, unless easy-to-use platforms such as GUIs can be 
developed. Therefore, to make the Bayesian approach more feasible for use by clinical and 
biomedical researchers, easy-to-use tools for conducting Bayesian analysis must be developed. 
Tools that require minimal interaction—such as input the experimental data and simple point-
and-click—while running the Bayesian prediction model in the background would have the most 
potential for real-world problem solving. 
4. Specific studies  
 In the current studies, we have developed Bayesian models and applied these models to 
two specific problems in health care and clinical study: (a) the development and assessment of 
patient reported outcomes and (b) the prediction of patient accrual (recruitment) in clinical trials. 
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 Patient-reported outcome measures are gaining in importance for the evaluation of 
clinical studies (NIH; Cella et al., 2010; FDA; Speight & Barendse, 2010). For some chronic 
diseases, the ultimate goal of clinical treatment not only is disease survival but the quality of life. 
In addition to physical, physiological or biochemical measures of a disease condition, patient-
reported outcomes on feedback and behavior changes provide crucial information regarding the 
treatment of disease (Deshpande, 2012). Unlike other clinical outcomes, such as blood pressure, 
fasting glucose, and lipid profile, patient reported outcomes cannot be measured by medical 
devices. Instead, they require a psychometric instrument (e.g., a questionnaire) with supporting 
documents. Constructing a valid instrument is both time consuming and expensive, especially in 
situations where measurement development requires patients  thatcome from small populations 
(e.g., American Indians) and/or suffer from orphan diseases (e.g., cryptogenic painful 
neuropathy). A valid and efficient instrument development method will help to expedite the 
process and thus be beneficial for studying the impact of treatment and disease on patients.  
 Subject recruitment is another challenge in medical research. Slow patient accrual leads 
to increased cost and resource utilization, especially the goodwill contribution of patient 
volunteers. When accrual is slow, researchers potentially will settle for smaller sample sizes than 
originally proposed. Consequently, slow accrual could result in a delay in the adoption of new 
therapies and slow the advancement of medical progress (Philipson et al., 2010). Overall, clinical 
trial monitoring of the accrual process is very important.  
 In the following chapters, Bayesian methods will be developed and applied to problems 
in health care evaluation.  In Chapter 2, Bayesian Instrument Development (BID) is introduced 
to examine patient reported outcomes. The stability of BID is evaluated using a simulation study, 
and user-friendly BID software also is proposed. The BID software can provide Bayesian 
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estimates of content and construct analysis for developing patient-reported outcome measures. 
Chapters 3 and 4 are studies of patient accrual monitoring in clinical trials. In Chapter 3, two 
hierarchical priors are introduced, and the properties of different priors are evaluated using data 
from clinical studies and simulations. Also in Chapter 3, user-friendly software for accural 
monitoring is described and details for its use are provided. The accrual software is used to 
predict the accrual at the end of a clinical trial given accrual to the present time, and can provide 
the probability that the trial will finish within the planned time frame or the time frame required 
to recruit the planned number of subjects.  The dissertation concludes in Chapter 5 with summary 
and future studies.  
  
20 
 
Figure 1-1. A graphical illustration of variance and bias, with (A) estimators are unbiased 
and have low variance (B) estimators are unbiased with high variance (C) estimators are 
biased with low variance and (D) estimators are biased with high variance.  
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(Published on Applied Psychometric Measurement) 
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Abstract 
 
Developing valid and reliable instruments is crucial but costly and time-consuming in 
health care research and evaluation. The Food and Drug Administration and the National 
Institutes of Health have set up guidelines for developing patient-reported outcome instruments. 
However, the guidelines are not applicable to cases of small sample sizes. Instead of using an 
exact estimation procedure to examine psychometric properties, our Bayesian Instrument 
Development (BID) method integrates expert data and participant data into a single seamless 
analysis. Using a novel set of priors, we use simulated data to compare BID to classical 
instrument development procedures and test the stability of BID. To display BID to non-
statisticians, a graphical user interface based on R and WINBUGS is developed and 
demonstrated with data on a small sample of heart failure patients. Costs were saved by 
eliminating the need for unnecessary continuation of data collection for larger samples as 
required by the classical instrument development approach.  
Key Words: BID, content validity, construct validity, patient reported outcomes, reliability 
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Introduction 
Patient reported outcomes (PRO), which specifically refer to self-reports by patients, play 
an important role in health care research, system evaluation, and drug approval. Both the 
National Institutes of Health (NIH; Cella et al., 2010) and the Food and Drug Administration 
(FDA; Speight & Barendse, 2010) have set up guidelines for developing and accessing patient 
reported outcome measurement instruments. As implied in the extensive guidelines, classical 
psychometric instrument development is a lengthy process. Establishing a valid and reliable 
instrument requires necessary but time-consuming data gathering on content validity and on 
construct evidence. Typically, researchers begin the instrument development process by first 
estimating content validity, which includes subject matter experts’ evaluations of the extent to 
which items match the theoretical definition of the construct (Crocker & Algina, 1986). 
Estimating content validity is based on an interpretive trait-based argument, thereby providing a 
framework for linking the target domain to items that are developed and revised based on content 
expert opinions (Polit & Beck, 2006). Expert opinions only are used for making decisions about 
item contents (i.e., evidence of content validity), such as removing non-relevant items, fine 
tuning the wording of items, or adding new items. Next, through the collection of data from 
participants, the reliability and construct validity of items are tested by examining item inter-
relationships using factor analysis methods or an item response theory (IRT) model, which is an 
ordinal version of factor analysis from a modeling standpoint (Beck & Gable, 2001).  In classical 
psychometric instrument development, the information provided by experts and by participants 
usually is analyzed separately. Information from the expert data (content analysis) is not used in 
a factor analysis (or IRT) of the participants’ data (Messick, 1989).  
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Classical psychometric instrument development typically requires a large number of 
subjects (Westland, 2010; Westland, in press). Identifying sufficient numbers of subjects, 
particularly when there are limited resources and/or small populations, is not optimal for the 
timely development of needed instruments.  For example, the development of an instrument for 
measuring outcomes for bipolar disorder took four years (Michalak & Murray, 2010).  Therefore, 
a valid method that requires fewer subjects and less time is needed to expedite collecting data for 
research and translating findings into practice.  The FDA and NIH do provide guidelines for 
factor analysis and IRT; however, they do not address situations for which targeted populations 
are small, which can arise when evaluating small racial or ethnic groups or patients suffering 
from rare disease. Lee (1981) developed a Bayesian approach for factor analysis and Lee and 
Song (2004) showed that it can be used for small sample sizes (N=50) while traditional factor 
analysis cannot.  Gajewski et al. (2013) developed a unified psychometric model that potentially 
needs fewer subjects in estimating validity evidence for establishing new instruments. The 
Bayesian approach integrates the analyses of the content and construct validity (IACCV; 
Gajewski, Price, Coffland, Boyle, &  Bott, 2013). In brief, the method first summarizes the state 
of knowledge of content validity using a prior probability distribution derived from expert 
judgment. The participant data are then used to update to a posterior distribution.  IACCV was 
first used on an instrument measuring nursing home culture change (Gajewski, Price, Coffland, 
Boyle, &  Bott, 2013). With this method, the investigators can transfer some of the response 
burden from the participants to an expert panel resulting in a faster, more efficient, and less 
costly instrument development process. 
In this paper, we further advance IACCV methodology and report an easy-to-use 
software package that will implement our Bayesian instrument development method targeted for 
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use by clinical researchers. Among the advancements, some are statistical and some are practical 
(e.g., software development). For example, in our previous work (Gajewski, Price, Coffland, 
Boyle, &  Bott, 2013), a logit transformation was used for item-domain correlations, which is too 
restrictive because it produces only non-negative correlations. In the current study, we use 
Fisher’s transformation (Wilks, 1962) because its range (1 to 1) is a real representation of 
correlation. To reflect these new advancements in IACCV in the form of our new software for 
clinical researchers, the current approach is called Bayesian instrument development (BID). 
Evaluation and comparison of the Bayesian approach to likelihood methods has been 
studied by many researchers (Chaloner, 1987; Browne & Drapper, 2006). In general, a Bayes 
estimator has a smaller squared error but a larger bias compared to a maximum likelihood 
estimator in analysis of variance components (Chaloner, 1987). Comparing the Bayesian 
approach to traditional factor analysis was first investigated by Lee (1981) using simulation 
studies. The results showed that Bayes estimates using “reasonably good prior information” are 
better than flat priors, and both of the estimates have smaller root mean square error than the 
traditional maximum likelihood factor analysis approach (Lee & Shi, 2000). Samaniego and 
Reneau (1994) presented a landmark study which showed both theoretically and empirically that 
Bayesian estimates perform better than frequentists’ when the priors are close enough to the 
truth. However, when the priors are highly misinformed about parameters, Bayesian estimates 
may lose their superiority and should be processed with caution . We have extended the study 
into a comparison of BID and traditional factor analysis for various levels of expertise:  some 
experts have a correct opinion and others have a wrong opinion. The effect of these 
“contaminated priors” on Bayesian factor analysis and its comparison to a classical approach is a 
main contribution of this paper.   
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Using simulated data, we test the BID approach by comparing it with classical instrument 
development in terms of performance stability and time consumption in development. The 
results will demonstrate that while the mean square error (MSE) of correlation estimation using 
classical instrument development does not change with respect to the number of experts, BID has 
lower error with even a single expert and further improves estimation efficiency as the number of 
experts increases. We will also demonstrate that the mean squared error for BID is smaller when 
compared to classical instrument development in the case when experts are biased by as much as 
50% and the number of biased experts is small (e.g., 1 or 2 biased experts out of 6 total experts). 
To make BID user-friendly, we programmed a graphical user interface (GUI) version of BID 
using R and WinBUGS (R Development Core Team, 2012; Lunn, Thomas, Best, & 
Spiegelhalter, 2000). The GUI version of BID can guide users to retain widely accepted 
principles (e.g., reliability, factor structure, or item characteristics) of instrument development by 
simple point and click. The new BID software is demonstrated to clinical researchers who are 
non-statisticians and applied to a research project Timeliness of Symptom Recognition, 
Interpretation, and Reporting in Heart Failure (TSRIR) (K99NR012217).  
BID model 
Bayesian Instrument Development (BID) expands Integrated Analysis of Content and 
Construct Validity (IACCV) that was first developed by Gajewski et al. (2013). In the current 
paper, we will focus on a one factor (domain) BID model. For details of the general model, 
please see Gajewski et al. (2013). Because of its general use in practice and simple analytic form, 
we motivate the factor analytic model with a simple illustrative calculation of item-domain 
correlation. 
Simple illustration: item to domain correlation  
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Suppose that the true distribution of item to domain correlation, after Fisher 
transformation, is normal; that is, 𝑔(𝑟)~𝑁(𝑔(𝜃),
1
𝑛
), where r is the sample item to domain 
Pearson’s correlation (e.g., standard calculation in psychometric software),  n is the number of 
participants, and g(.) is a function, Fisher’s transformation. Then, suppose the likelihood of 
correlation in a transformed scale can be written as 𝑔(𝑟)|𝑔(𝜌)~𝑁(𝑔(𝜌),
1
𝑛
). The prior for experts 
has a normal distribution after Fisher transformation 𝑔(𝜌)~𝑁(𝑔(𝜌0),
1
𝑛0
), where g(ρ0) is the 
transformed prior mean item to domain correlation and n0 is the prior sample size. The posterior 
distribution of g(ρ) is then 𝑔(𝜌)|𝑔(𝑟)~𝑁(
𝑛𝑔(𝑟)+𝑛0𝑔(𝜌0)
𝑛+𝑛0
,
1
𝑛+𝑛0
), where the mean is a linear 
combination of the transformed sample correlation and the prior mean, weighted by their 
respective sample sizes.  The variance is simply the inverse of the sum of the observed and prior 
sample sizes.. After assuming a true but unknown fixed correlation, θ, we can calculate the mean 
squared error using the standard formula 𝑀𝑆𝐸(𝐸[𝑔(𝜌)]) = 𝑉𝑎𝑟(𝐸[𝑔(𝜌)]) + 𝐵𝑖𝑎𝑠2, where 
𝐸[𝑔(𝜌)] is the Bayes estimate for 𝑔(𝜌).  Thus using standard expected value calculations we can 
see that 𝐵𝑖𝑎𝑠 =
𝑛𝑔(𝜃)+𝑛0𝑔(𝜌0)
𝑛+𝑛0
− 𝑔(𝜃) =
𝑛0(𝑔(𝜌0)−𝑔(𝜃))
𝑛+𝑛0
.  Further, using standard variance 
calculation 𝑉𝑎𝑟(𝐸[𝑔(𝜌)]) =
𝑛2
(𝑛+𝑛0)2
1
𝑛
=
𝑛
(𝑛+𝑛0)2
, and so the mean squared error is 
𝑀𝑆𝐸(𝐸[𝑔(𝜌)]) = 𝑉𝑎𝑟(𝐸[𝑔(𝜌)]) + 𝐵𝑖𝑎𝑠2  =
𝑛
(𝑛+𝑛0)2
+
𝑛0
2
(𝑛+𝑛0)2
(𝑔(𝜌0) − 𝑔(𝜃))
2. It is easy to 
show that using the MSE that BID is better than classic when  
𝑛
(𝑛+𝑛0)2
+
𝑛0
2
(𝑛+𝑛0)2
(𝑔(𝜌0) −
𝑔(𝜃))2 <
1
𝑛
, or (𝑔(𝜌0) − 𝑔(𝜃))
2 < (
1
𝑛
−
𝑛
(𝑛+𝑛0)2
)
(𝑛+𝑛0)
2
𝑛02
.  Suppose the prior sample size is 
n0=30 and data sample size is n=77.  Using the inequality, BID is better than classical method 
when (𝑔(𝜌0) − 𝑔(𝜃))
2 < (
1
𝑛
−
𝑛
(𝑛+𝑛0)2
)
(𝑛+𝑛0)
2
𝑛02
= (
1
77
−
77
(77+30)2
)
(77+30)2
302
=0.079654.  
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 Missing from this illustrative example is a methodology for specifying the prior 
distribution as well as specification to a more general model like factor analysis.  We explore 
these issues in the following sections and develop an estimation approach faster than Gajewski et 
al. (2013) for our simulations studies to calculate the mean squared error for a comparison of 
BID and the classical approach.  
Model and computation for experts 
For classical content validity, content experts are instructed to review all items and to 
“…indicate how relevant you perceive the item to be to the respective domain.” For each item, 
the rating scale generally ranges from 1 indicating ‘not relevant’ to 4 signifying ‘highly 
relevant’.  A recent study showed that content validity can also be measured using correlation 
scales, which are equivalent to relevance scales (Gajewski et al., 2012). Therefore, in addition to 
relevancy, content validity can be further interpreted as the experts’ opinion regarding item-to-
domain correlation.  
For the content expert data, suppose there are K experts (k = 1, 2, 3, …, K) responding to 
p questions (j = 1, 2 ,3, …, p) and let xjk
 
represent the ordinal measure of the kth expert’s opinion 
for the jth item’s relevance.  The correlation for the jth item with its respective domain as 
perceived by the kth expert is denoted by jk and its assumed mapping from xjk is as follows:      
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The correlation between the item and domain after pooling information from all experts 
is expressed as ),( jj zfcorr , where f, the factor score of the domain, has a standard normal 
distribution with mean of zero and variance of one, and zj is the standardized response for item j.  
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The thresholds of ρj are argued under the assumption that the experts view correlations using 
Cohen’s cut points (Cohen, 1988).  Equation (1) allows us to properly model the uncertainty in 
these correlations that is induced by the interval censoring (e.g., < 0.10, < 0.30, etc.), similar to 
other methods used in studies on pressure ulcer staging (Gajewski, Hart, Bergquist, & Dunton, 
2007), hearing test for audiology (Gajewski, Sedwick, & Antonelli, 2004; Gajewski, Nicholson, 
& Widen, 2009), and instrument development measuring nursing home quality of life (Gajewski, 
Price, Coffland, Boyle, &  Bott, 2013). Under some circumstances, if the prior data are from a 
panel knowledgeable in the area but not considered experts, an equal space transformation is 
found to be more appropriate and closer to actual correlations than the unequally spaced 
transformation (Gajewski et al., 2012; Pawlowicz et al., 2012). Equation (2) shows the equally 
spaced model: 
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(2)  
Using Fisher’s transformation, j  is transformed to  
j
j
j log)(g
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(3)
 
  
A hierarchical model that combines experts and includes all items is:  
jkjjk egg  )()(  , (4) 
where ejk is the random error assuming ejk~i.i.d. N(0,σ
2).  
 
Assuming a lack of information on content validity prior to eliciting expert judgment, we 
use an essentially flat prior σ2~IG (.00001, .00001) and g(ρj)~N(0, 3
2). The shape and rate 
parameters for inverse gamma (IG) are both 0.00001.  The prior specification allows us to 
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estimate the posterior distribution of ρj using the expert’s data via a Markov chain Monte Carlo 
(MCMC) procedure implemented in the software WinBUGS.  These results then form the prior 
distribution of ρj and are combined with the likelihood generated by participant data in the 
construct validity and reliability analysis. Note that this is a pool of expert’s data for a simple, 
compromised prior, which is different from Samaniego & Reneau (1994), who analyze single 
expert at a time.   
The previous model (Gajewski, Price, Coffland, Boyle, &  Bott, 2013) for expert data 
utilized a logit transformation of correlation.  However, because its range is 0 to 1 it can only be 
applied after reverse scoring items that are negatively correlated with the domain.  For this 
reason, the logit transformation might be too restrictive.  Using Fisher’s transformation in the 
current model allows a real line representation of correlation from 1 to 1.  
Based on our previous studies for nursing home culture change and nurse job satisfaction, 
we have found that the distribution of g(ρj) can be approximated normal. The variance of g(ρj) 
has an inverse relationship with the number of experts. That is, it is a simple representation of the 
sample size for the Bayesian prior. Specifically, the distribution of g(ρj) can be written as  
   0
0
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~ ,j j
j
g N g
n
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(5) 
where 
0 5jn K  and K is the total number of experts.  Thus, the above equation is used in the 
simulation study. And it assumes each expert is worth five participants. The calculation of the 
variance and the justification of this estimation can be found in the Appendix. This 
approximation is not used in the actual BID software, but rather is used to study the one-factor 
analytic model’s properties via simulation. 
 
Model and computation for participants 
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For construct validity, we use a standardized factor analytic model to describe the item-
to-domain correlations for participants’ data (Gajewski, Price, Coffland, Boyle, &  Bott, 2013). 
Specifically, the one factor (domain) model is: 
ijijij efz   .                                                                                                                      (6) 
 Assuming yij is the i
th subject‘s response to the jth item, it is standardized to zij, which 
allows us to focus on estimating item-to-domain correlations.  The total number of participants is 
n and the total number of items is p; if is the factor score for the domain (e.g., overall pain); and 
is typically assumed to follow a standard normal distribution, N (0, 1).  The correlation between 
ijz and if  is represented by j ; thus, 
2
j is the “reliability” of item j ((Alonso, Laenen, 
Molenberghs, Geys, & Vangeneugden, 2010).  The assumption ijz ~ N(0, 1) implies ije ~N(0,
2
1 j ). Thus, the likelihood for ijz  is:  
   2
1 1
| , | ,1
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ij j i j
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L N z f
 
 z ρ f   .                                                                                 (7) 
As discussed previously, the distribution of g(ρj) is approximately 
normal 𝑔(𝜌𝑗)~𝑁(𝑔(𝜌𝑗0), 𝜎
2
𝑔(𝜌𝑗0)
) . To estimate the posterior distribution of the jth component 
of ρ, a flat prior N(0, 32), representing high prior uncertainty in the construct validity of items 
can be used.  An informative prior can also be utilized by obtaining the mean and variance of 
𝑔(𝜌𝑗0) from content analysis using method of moments. In our simulation study, 
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 
   is used for the informative prior.  Using this prior, the posterior 
distribution is: 
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The estimation of the posterior distribution of ρ can be obtained by MCMC methods performed 
in R and WinBUGS.  However, this process is unnecessarily slow for simulation tests where 
only the posterior mode is needed.  For example, when the number of items is 8 and the sample 
size is 100, it takes about 10 hours to compute 1,000 iterations using Equation (8) on a shared 
high speed workstation with dual Xeon 3.6 GHz processors and 4 GB of SDRAM. 
Equation (8) provides the full posterior distribution that we use for clinical research, as it 
contains all the information for our inference. Although the posterior distribution does not have a 
closed form solution, it can be simplified because zi follows a multivariate normal distribution, zi 
~MVN(0, R). The variance of zi is 1, the covariance between ijz  and ikz  is the product of ρi and 
ρj, and R is  
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Then, the posterior distribution can be simplified as: 
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The specific estimation of ρj’s can be obtained by calculating the posterior mode of (10), which 
is the minimum of the following formula: 
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with constant, C. The estimation of ρj’s can be obtained by using the “nlminb” function in R, 
which is an optimization procedure using PORT routines (Bates & Sarkar, 2012). It has been 
shown in the literature (Lee, 2007) that using multivariate-based equations, like Equation (11), 
for estimating the full posterior distribution is slower than using univariate-based equations, like 
Equation (8). However, we only need the posterior mode for our simulation study, so using 
Equation (11) is actually much faster and more convenient.  For example, the processing time is 
reduced to about 5 minutes for the same analysis as described above using Equation (8).  
Calculation of item reliability 
In addition to validity, reliability is also an important concept in instrument development 
because it represents the precision of measurements. Cronbach’s alpha has been widely used in 
the estimation of reliability.  However, it is a lower bound estimator (Green & Yang, 2009), and 
therefore a conservative assessment of reliability.  It is better to estimate composite reliability via 
a model based approach (Alonso, Laenen, Molenberghs, Geys, & Vangeneugden, 2010).  
Under the one factor model, equation (6) also can be written in matrix form: 
i i if ρz e  
where,  1 2, , ,i i i ipz z z z  and  1 2, , , .p ρ     
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According to Alonso et al. (2010), the entire reliability is: 
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34 
 
where zi ~ MVN(0, R) , and ei ~ MVN(0, Σ).  Entire reliability measures the reliability of the 
whole domain of items.  Our extension using BID allows for efficient estimation of reliability for 
small populations.  
Simulation study 
We use simulated data to evaluate the performance of BID and compare it to the 
traditional factor analysis, a common approach for validating statistical methods.  In BID, we 
assume all experts agree in interpreting the notion of correlation in their judgment response. 
Furthermore, experts’ data are correlated with participants’ data, indicating their judgments are 
the same or highly similar. To understand how violations of these assumptions may affect the 
analysis of data from expert opinion, we will test violations of the assumptions about 
performance of the experts. Using simulation, we will see more clearly the benefit-to-cost ratio 
of the number of experts needed for adequate evidence of content validity, and it will allow for 
exploration of the sensitivity of our assumptions regarding the experts’ judgments.  
According to our previous job satisfaction study, the average of the correlations ρ 
between individual item and domain is 0.5 (Gajewski, et. al., 2012); therefore, we will assume 
the true correlation is ρTRUE = 0.50 for all items. Under this assumption the scale score would 
explain 25% of the variation in the corresponding item. We obtain the Bayesian estimate—the 
posterior mode—using R instead of using the MCMC procedure in R and WINBUGS that 
estimates the full posterior distribution.  The latter is used in our R-GUI BID software developed 
for clinical study researchers (see section 4). For comparison to traditional methods, classical 
factor analysis is done using the “Lavaan” package built in R (Rosseel, 2012).  The numerical 
results of the “Lavaan” package are typically very close to that of the commercial package Mplus 
(Rosseel, 2010).  
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We test BID under two scenarios. First, we examine the stability of BID using different 
assumptions (unbiased experts ρ0=0.50 or biased experts ρ0=0.75), as the experts tend to 
overestimate the relevance of items in content validity (Gajewski, Price, Coffland, Boyle, &  
Bott, 2013).  Specifically, we assume the prior distributions are     10~ 0.5 ,j jg N g n
 
or 
    10~ 0.75 ,j jg N g n .  We then test BID performance when prior distributions (experts) are 
a mixture of unbiased and biased information. 
Biased or unbiased priors 
In order to test the performance of BID under biased prior expert information, we use a 
four factor simulation design. The first simulation factor is the presence or absence of expert 
bias—either (1) the judgment of correlation between experts provides estimates of the square 
root of item reliability (ρ0=0.50, unbiased for all items), or (2) the experts are biased (ρ0=0.75, 
for all items). We also examine the impact of bias over a range of number of items (8, 16, or 24), 
number of subjects (50, 100, or 200) and number of experts (1, 2, 6, or 16), which are typical 
instrument development studies with small sample sizes (Polit & Beck, 2006).   
We use R to generate participant data based on the assumption that the standardized item 
response zi is multivariate normal with mean vector zero and variance of identity.  Each factor 
combination simulation is repeated for 1,000 times.  Let )(ˆ sj be the posterior mode for the s
th 
simulation in a total of 1,000 iterations.  Then 
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Figure 2-1 shows the MSE correlation estimates for unbiased and biased experts with 
participant sample sizes of 50, 100, or 200 when the number of items is 8. As traditional factor 
analysis does not use content validity information, it is not surprising that the MSE is unaffected 
by prior information.  When the priors are unbiased, the MSE obtained by BID is always smaller 
than classical factor analysis when the sample size is 50 or 100, indicating BID is more efficient.  
When the sample size is large (n=200), the MSE by classical factor analysis is slightly smaller 
than that of BID only when the number of experts is one. As the number of experts increases, the 
gains in efficiency by BID also increase.  However, when the priors are biased, the relative 
efficiency of BID compared to classical factor analysis is a function of the number of experts. 
When the number of experts is small (e.g., one or two), BID has lower MSE than traditional 
methods.  As the number of experts increases, any gains in efficiency recede and eventually 
traditional methods become superior. When sample size is smaller (e.g., n=50), efficiencies 
gained by BID are most obvious. The differences in MSE when using BID versus classical factor 
analysis follow a similar pattern when the number of items is 16 or 32. The corresponding 
figures are shown in the supplemental sections.   
Overall, our first simulation study shows the impact of biased experts on the efficiency of 
BID relative to traditional methods is a function of the number of biased experts.  When the 
expert data are unbiased, the MSE is always smaller when using BID rather than classical factor 
analysis for samll sample studies. However, a stubbornly biased subjective prior is quite harmful. 
Our findings are consistent with those discussed in other Bayesian literature investigating 
Bayesian and classical estimation (Samaniego and Reneau 1994, Garthwaite, Kadane, & 
O’Hagan, 2005). 
Contaminated priors 
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A second simulation study assessed the impact of having a contaminated expert panel; 
that is, assuming the number of experts is six and we investigated the impact of having one or 
two with biased judgment.  Here, we let c represent the number of biased experts and examine 
the effects of prior contamination for participant sample sizes of 50, 100, and 200; and numbers 
of items of 8, 16, and 24. 
We investigated the theoretical distribution of g(ρ) when the total number of experts is 6, 
and the number of biased experts (ρ0=0.75) is c = 0, 1, 2, or 6, respectively. When all experts are 
unbiased (ρ0=0.50), the distribution of g(ρ) is normal with mean 0.5log(3) and variance 1/30. The 
distribution of g(ρ) shifts to the right when there is one biased expert in the panel. The upper tail 
becomes heavier when contaminated priors increase to two.  When all the experts are biased, the 
distribution of g(ρ) changes back to a normal distribution with mean 0.5log(7), and variance 
1/30. The theoretical distributions of g(ρ) and ρ are shown in supplementary figures 2-S1A and 
2-S1B.  
Similar to the first set of simulations, R was used to generate data and calculate the 
posterior mode for ρ, and 1,000 iterations were carried out for each simulation scenario. The 
MSE shown in the graph is MSE from the 1,000 replications. 
As shown in Figure 2-2A, compared to classical factor analysis, BID always has a lower 
MSE of correlation estimates when the number of biased experts is one or two for a panel with 
six experts.  Fewer contaminated priors are always better, as the data shows the MSE with only 
one biased expert is lower than that of two biased experts.  The results are very similar across 
participant sample sizes of 50, 100 and 200, but the gain in efficiency decreases as the number of 
participants increase. Our results show that when the number of items is 8, the MSE of BID with 
one contaminated priors is equivalent to the MSE from a classical CFA method (MSE = 0.01). 
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However, the level of precision is achievable with half the number of participants (n = 100 for 
CFA, n = 50 for BID). Figure 2-2B shows the bias2 of correlation estimates. The square of bias is 
larger using BID when there are biased experts in the panel compared to the classical method. 
The results of bias2 indicated that BID lowers MSE through decrease of variance. Overall, 
estimation using informative priors is more efficient, which confirms the novel finding of 
Samaniego and Reneau (1994). 
Application to data from heart failure study and development of GUI-BID software 
We programmed a graphical user interface (GUI) version of BID using “TclTk” and 
“fgui” package in R and WinBUGS (Grosjean, 2012; Thomas & Nan, 2009).  The new user-
friendly BID software was readily usable by clinical researchers who were non-statisticians. An 
example of the GUI-BID software window can be found in figure 2S-4. The clinical researchers 
can choose to use a flat prior or an informative prior from expert data by selecting the option 
“prior” to be true or false.  Data loading for both expert and participant data is accomplished by 
using the BID software in a point and click environment. The users are also guided to add the 
factor structure for the instrument.  Although we focused on a one factor model for this paper, 
the software applies to multi-factor models as well. 
In a study of heart failure, we apply BID to develop an instrument with the purpose to 
assess symptoms in heart failure patients.  Using the proposed instrument, Timeliness of 
Symptom Recognition, Interpretation, and Reporting in Heart Failure (TSRIR) (K99NR012217), 
the study is conducted by nursing researchers to examine the symptom experiences of patients 
with heart failure leading up to hospitalization for acute decompensated heart failure. The tested 
instrument has ten items, and the experts’ ratings are on a 1-4 scale, from “not relevant” to 
“highly relevant”.   
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First, the experts’ data are analyzed using the Bayesian approach with equal space 
transformation discussed in section 3.  In the MCMC procedure for estimating ρj we used three 
chains and a burn-in of the first 2,000 draws of each chain.  The next 10,000 iterations were used 
for inferences.  We also perform BID on participant data using a flat prior; that is, using g(ρj) ~ 
N(0,32) in the BID model.  The results are shown in Table 2-S1. The entire reliability using the 
flat prior specification is 0.943, and its standard deviation is 0.010.   Using an informative 
prior, 𝑔(𝜌𝑗)~𝑁(𝑔(𝜌𝑗0), 𝜎
2
𝑔(𝜌𝑗0)
) , with an equal spaced model, the total reliability is 0.938 with 
standard deviation equal to 0.007.  According to NIH PROMIS cut points, the reliability is larger 
than 0.8 and should be considered substantial (Cella et al., 2010).  Overall, in the heart failure 
study the dimensions (scales) were deemed reliable with a small sample size (n = 60) using BID.  
Discussion 
 
 Classical instrument development is a powerful tool in patient reported outcome 
measurements when one has easy access to a large number of participants and considerable 
resources. However, in practice it usually happens that either the numbers of participants or 
resources are limited.  Using a Bayesian approach, BID provides an innovative method for 
instrument development.  BID is particularly valuable for studies with limited participants, such 
as studies involving minority groups or those with orphan or rare diseases.  In the heart failure 
study, it is notable that it took over two years to obtain data from 60 patients. The ratio of the 
variance of reliability by flat prior to informative prior is 0.012/0.0072=2.04.  Thus, 104% more 
data or 123 participants would be needed if using traditional approaches.  Consequently, it took 
two years to gain this clinical data, and it would take at least two more years without the 
informative prior. Using the BID approach, the clinical researchers do not need to continue data 
collection to obtain a larger sample that would be required by the classical instrument 
40 
 
development approach. Both cost and time savings are achieved. Even when large samples are 
available, limited resources still may present challenges for investigators. For example, the 
development of an instrument measuring smoking cessation practices in methadone treatment 
clinics took four years because funds were limited for both participant incentives and personnel. 
If using BID, the processes could speed up dramatically (Cupertino et al., in review). Overall, 
BID proposes a psychometrically comprehensive and statistically efficient method for instrument 
development.  
Using indirect measurement information is an important trend in statistics and related 
areas (Efron 2010). Samaniego and Reneau (1994) revealed that a good utilization of this 
indirect information, in the form of a prior distribution, can lead to a Bayesian estimator which is 
superior to a frequentist estimator in most situations. We extended their study into factor analysis 
for estimation of construct validity. In the current paper, we provided a full comparison of 
Bayesian approach and traditional factor analysis using simulation studies. In this paper, we 
investigated the performance of the Bayesian approach under different conditions: (1) the priors 
(experts) are all unbiased, (2) the priors (experts) are all biased (3) the priors are contaminated, 
with 1 or 2 biased experts among a total of 6 experts.  Our results are consistent with what was in 
Lee (1981, Lee & Shi 2000), which shows that the Bayesian approach performs better than 
traditional factor analysis when using a flat or “good informative” prior. Our results are 
consistent with Samaniego and Reneau (1994)’s general finding that a Bayesian estimate is 
always superior to a frequentist estimate if the bias in the Bayesian prior is smaller than the 
sample standard deviation.  In addition, we showed more clearly that the Bayesian approach is 
practically better than traditional methods, especially for small sample sizes as in our heart 
failure example. 
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 Although the current study focuses on a one factor model, BID can easily be applied 
to multi-factor models. For the heart failure study data, we also tried different factor structures 
(i.e., using multiple factors and/or fewer items). The results were consistent with the expected 
results. In the BID model, we assume the experts’ opinion on items is independent and our prior 
is weighted over all the experts. The assumptions were used to simplify the model. However, in 
real circumstances the experts’ opinions on items are most likely correlated. In future studies, a 
correlated model may provide a better estimation for the content validity.  A hierarchical model 
could be used to allow for individualized priors for each expert based on their prior beliefs. This 
would provide us with the ability to evaluate the effect of a single expert on the analysis and 
draw conclusions, using an approach similar as discussed by Samaniego & Reneau (1994). In 
BID, we also assume the participants’ data are continuous; however, many clinical 
questionnaires are in ordinal or binary form. Therefore, Ordinal Bayesian Instrument 
Development (OBID) using item response theory is a topic for future work.  
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Figure 2-1. Mean Square Error correlation estimates ρ in stimulation study using BID 
(dashed line) and classical factor analysis (solid line) when the number of items is 8. The 
number of experts are 1, 2, 6, and 16, and they are either unbiased (ρ0=0.5, left panel) or 
biased (ρ0=0.75, right panel). The participant sample sizes are 50 (A and B), 100 (C and D), 
and 200 (E and F).  
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Figure 2-2. Mean Square Error (A) and Square of bias (B) of correlation estimates ρ in 
stimulation study using classical factor analysis, BID modeling with a panel of six experts 
containing one biased prior (C = 1), and BID modeling with a panel of six experts 
containing two biased priors (C = 2) when participant sample size is 50 (a), 100 (b) and 200 
(c).  All scenarios assume a true correlation ρ0=0.5 with biased expert judgment of ρ0=0.75. 
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Table 2-S1. The posterior means, standard deviations and 2.5, 50, 97.5 percentage quintiles 
for the participant data analyzed using BID with flat priors (A) and BID with informative 
priors using equal space transformation (B).  
A) Flat prior  
  mean sd 2.5% 50% 97.5% 
item1 -0.034 0.132 -0.286 -0.016 0.195 
item2 0.176 0.124 -0.049 0.172 0.413 
Item3 0.364 0.126 0.090 0.377 0.587 
Item4 0.432 0.115 0.152 0.455 0.596 
Item5 0.177 0.162 -0.142 0.173 0.487 
Item6 0.920 0.028 0.848 0.925 0.964 
Item7 0.829 0.041 0.743 0.834 0.901 
Item8 0.927 0.025 0.862 0.931 0.961 
Item9 0.455 0.104 0.226 0.461 0.633 
Item10 0.532 0.093 0.322 0.537 0.690 
RΛ 0.943 0.010 0.921 0.944 0.961 
B)  Informative prior (“Equal” spaced) 
  mean sd 2.5% 50% 97.5% 
item1 0.493 0.063 0.357 0.499 0.600 
item2 0.578 0.053 0.471 0.582 0.675 
Item3 0.713 0.040 0.628 0.714 0.786 
Item4 0.668 0.050 0.559 0.675 0.746 
Item5 0.601 0.059 0.471 0.602 0.711 
Item6 0.879 0.025 0.819 0.881 0.922 
Item7 0.857 0.025 0.803 0.859 0.901 
Item8 0.881 0.021 0.832 0.884 0.914 
Item9 0.637 0.052 0.532 0.638 0.729 
Item10 0.663 0.050 0.549 0.665 0.749 
RΛ 0.938 0.007 0.925 0.937 0.948 
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Figure 2-S1 Distribution of (A) transformed priors g(ρ) and (B) untransformed priors ρ 
when the total number of experts is 6 for all unbiased experts (c = 0),  one biased expert (c 
= 1), two biased experts (c = 2), and all biased experts ρ0=0.75 (c = 6).  All scenarios assume 
a true correlation (unbiased) ρ0=0.5 with biased expert judgment of ρ0=0.75. 
(A) 
 
 
 
 
 
 
 
 
 
 
B) 
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Figure 2-S2. Mean Square Error correlation estimates ρ in stimulation study using BID 
(dashed line) and classical factor analysis (solid line) when the number of items is 16. The 
number of experts are 1, 2, 6, and 16, and they are either unbiased (ρ0=0.5, left panel) or 
biased (ρ0=0.75, right panel). The participant sample sizes are 50 (A and B), 100 (C and D), 
and 200 (E and F).  
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Figure 2-S3. Mean Square Error correlation estimates ρ in stimulation study using BID 
(dashed line) and classical factor analysis (solid line) when the number of items is 24. The 
number of experts are 1, 2, 6, and 16, and they are either unbiased (ρ0=0.5, left panel) or 
biased (ρ0=0.75, right panel). The participant sample sizes are 50 (A and B), 100 (C and D), 
and 200 (E and F).  
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Figure 2-S4. A typical GUI-BID window that guides the clinical researchers analyzing data 
using BID.  
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Appendix. Justification of experts equivalents 
 BID has been used in the study of nursing home culture change (Gajewski et al., 2011) 
and job satisfaction in nursing faculty members (Pawlowiz et al., 2012; Gajewski et al., 2012). 
Both studies report the estimation of the correlation of item-to-domain; that is, ρj. Using Fisher’s 
transformation: 
j
j
jg






1
1
log
2
1
)(
                                                                                                   (A1)                                  
If the variance of ρj is V, then by the delta method, the variance of g(ρj) is 
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Then, the variance of g(ρj) can be calculated and the expert equivalent is estimated to be five. 
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Abstract 
 
Slow recruitment in medical research leads to increased costs and resource utilization, which 
includes the goodwill contribution of patient volunteers. Careful planning and monitoring of the 
accrual process can prevent the unnecessary loss of these resources. We propose two hierarchical 
extensions to the existing Bayesian constant accrual model: the accelerated prior and the hedging 
prior. The new proposed priors are able to adaptively utilize the researcher’s previous experience 
and current accrual data to produce the estimation of trial completion time. The performance of 
these models, including prediction precision, coverage probability, and correct decision-making 
ability, is evaluated using actual studies from our cancer center and simulation. The results 
showed that a constant accrual model with strongly informative priors works very well when 
accrual is on target or slightly off, producing smaller mean squared error, high percentage of 
coverage, and a high number of correct decisions whether or not continue the trial, but it is 
strongly biased when off target. Flat or weakly informative priors provide protection against an 
off target prior, but are less efficient when the accrual is on target. The accelerated prior 
performs similar to a strong prior. The hedging prior performs much like the weak priors when 
the accrual is extremely off target, but closer to the strong priors when the accrual is on target or 
only slightly off target. We suggest improvements in these models and propose new models for 
future research. 
 
 
Key Words: clinical trials, hedging prior, objective prior, patient accrual, data monitoring 
committee 
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1. Introduction 
Evaluating and monitoring subject recruitment is important in medical research (Schroen, 
et al., 2010).  Delayed subject recruitment will increase the cost of study and/or can lead 
researchers to settle for smaller sample sizes than originally proposed. If the proposed sample 
size is not achieved, the study will have low power and may fail to recognize a treatment effect. 
Slow recruitment tends to increase resource utilization, which includes the goodwill contribution 
of patient volunteers. The delayed recruitment may also lead to delay in the adoption of new 
therapies and slow the advancement of medical progress (Philipson, et al., 2010). For example, a 
year delay in access to Herceptin would represent a total loss of $8 billion dollars of benefit for 
breast cancer patients in the United States (Parreco, 2012). Development of reliable and practical 
tools for accrual prediction is critical in clinical trial studies.  
Modeling subject recruitment has been studied for a long time. The available accrual 
models are reviewed by Barnard (2010) and Zhang (2012a). According to Barnard (2010), the 
simplest approach is an unconditional model (Carter, 2004). It assumes the accrual rate (e.g., 
subjects recruited per month) is fixed. The total accrual time is estimated through dividing the 
planned sample size by the number of subjects they expect to recruit each month. A conditional 
model allows the accrual rates to vary in any given time depending on other factors that may 
accelerate or delay the accrual (Carter, Sonne, & Brady, 2005). Compared to the unconditional 
model, the conditional model matches more closely to real situations. Both unconditional and 
conditional models fail to consider variations in actual accrual progress, and therefore, their 
predictions are less accurate. The Poisson models assume that the number of participants 
recruited within a fixed time follows a Poisson distribution (Carter, Sonne, & Brady, 2005). 
Anisimov and Fedorov (2007) applied the Poisson model to multi-center clinical trials, assuming 
54 
 
that the rate parameter for the Poisson was different for each center of a multi-center study, and 
overall the accrual process followed a Poisson-Gamma distribution. Bakhshi, Senn and Phillips 
(2013) extended the approach with a hierarchical model using historical data from similar trials 
in the specific center via an empirical Bayesian approach.  Some other models have also been 
proposed, such as the Monte Carlo simulation Markov model by Abbas (2007), time series 
model by Hadich and Ioannidis (2001), and a model based on nonhomogeneous Poisson process 
by Zhang and Long (2012b). 
Gajewski, Simon and Carlson (2008) developed a Bayesian method for constant accrual 
based on an exponential waiting model, which is equivalent to Poisson counts over a specified 
time (Casella & Berger, 2002, p. 100). A unique feature of this model is the incorporation of 
subjective knowledge about accrual rates through an informative prior distribution (Gajewski, 
Simon & Carlson, 2008). The strength of the prior distribution is controlled by a parameter P 
between 0 and 1. If P=1, the prior is given weight equivalent to the proposed sample size of the 
study. If P=0.5, the prior is given weight equivalent to half the proposed sample size. This means 
that halfway through the study, the prior and the actual accrual data are given equal weight. If 
P=0, the prior is effectively ignored (Gajewski, Simon & Carlson, 2008). If the researcher has 
strong confidence in accrual (for example, he/she has extensive research experience with many 
similar studies in the same patient setting), the posterior distribution will be weighted heavily 
towards the prior distribution, especially early in the trial. This avoids an unnecessary alarm 
when the first few subjects arrive more slowly than expected. On the other hand, if the researcher 
has a weak prior, early evidence of slow accrual will be given greater weight, encouraging a 
rapid response to address the slow accrual (Gajewski, Simon & Carlson, 2008).  
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As discussed above, assessment and specification of control parameter P is critical in 
simple constant accrual model (Gajewski, Simon & Carlson, 2008). The researchers should 
constantly monitor/change prior P subjectively during the accrual process, and the assessment of 
P is totally based on researchers’ knowledge and previous experience. There are several 
limitations regarding this method. One of the most concerns is researchers’ over-confidence. 
What if the researcher provides a strongly informative prior distribution that is substantially off 
target? This is, unfortunately, quite common. In our experience, researchers are frequently overly 
optimistic about accrual rates and they are overly confident in their estimates. This experience 
has been noted by others as well. For example, a study of 78 projects in eight departments of 
general practice conducted at the Netherlands Institute for Health Services Research and the 
Centre for Quality of Care Research, found that only 46% recruited the planned number of 
patients within the planned time frame (van der Wouden, et al., 2007). Other examples of this 
overconfidence can be found in Williams and Seed (2006), Breau, Carnat, and Gaboury (2006), 
Jayakaran  Saxena, and Yadav (2011), Keen, Pile, and Hill (2005). As we know, mis-spefication 
of prior by researchers will lead to huge bias in the prediction of accrual, which in turn impairing 
the management of the trial.  Another concern of the existing method is the assessment of P is 
not always practical. A third party, who lacks sufficient knowledge in the specific trial, may have 
difficulty to specific P. For example, when the clinical trial is evaluated by the IRB, it will hard 
for the committee to propose an appropriate subjective prior P to evaluate the trial process. This 
lack of sufficient message may also introduce bias in P.   
To avoid a poor choice of prior mean, a more general and objective approach is to 
incorporate the historical opinion through power prior (Ibrahim & Chen 2000). The power prior 
was evaluated and modified by several groups of researchers, which is now well recognized as 
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the modified power prior (Duan, Ye, & Smith, 2006; Neuenschwander, Branson, & Spiegelhalter 
2009). The borrowing strength of historical data is controlled by power parameter. If the power 
parameter is 0, it borrows on historical information. On the other hand, if the power parameter is 
1, it borrows full historical information. Another way to utilize historical data is through 
commensurate power prior, which is proposed by Hobbs et al. (2011).  
 In this paper, we propose two adaptive Bayesian priors in monitoring accrual process. 
The first one is the accelerated prior. The initial prior probability (P) is associated with the 
proportion of data collected. In the beginning of the trial, when no data are collected, the model 
will weigh entirely on the investigator’s historical experience, with P=1. As data collection 
progresses, P declines linearly. This puts less weight on the prior and more weight on the data. 
While all Bayesian models place less weight on the prior as data collection progresses, the 
accelerated prior speeds up this process to avoid the lingering effects of an off target prior. 
 The second approach we proposed is the hedging prior. This model treats P as a 
hyperparameter which follows a uniform distribution. If the prior is off target, the 
hyperparameter converges to zero as more accrual data arrives. The hedging prior is equivalent 
to the modified power prior, but the hedging prior is much simpler to implement.  
 With adaptive priors, P is monitored and determined with the process of the trial. 
Detailed model descriptions are provided for the accelerated prior and the hedging prior in 
section 2. Section 3 shows the application and evaluation of the methods using real clinical data. 
In section 4, the model efficiency and robustness of the new proposed methods and the previous 
proposed Bayesian model are examined using simulated data under nine different scenarios. 
Section 5 is the discussion and conclusions.  
Model 
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2.1 Closed form of constant exponential waiting time model 
 Gajewski, Simon & Carlson (2008) introduced a Bayesian model for constant accrual. 
Suppose in the original protocol, the investigator planned to recruit n subjects in T days. Assume 
that the waiting time (w) for each successive patient follows an exponential distribution, 
𝑤𝑖~exp (𝜃), where θ represents the average accrual time for the ith subject. The distribution of 
the waiting time (w) is 𝑓(𝑤|𝜃) =
1
θ
𝑒−𝑤/𝜃.  The prior distribution of 𝜃 is assumed to be inverse 
gamma, 𝜃~𝐼𝐺(𝑛𝑃, 𝑇𝑃), where P is the investigator’s confidence in the original plan, measured 
on a 0-1 scale. During the trial, m subjects have been collected in 𝑇𝑚 (𝑇𝑚  = ∑ 𝑤𝑖
𝑚
𝑖=1 ) time 
period. Then the posterior distribution for 𝜃 is updated to 𝜃|𝑾~IG(𝑛𝑃 + 𝑚, 𝑇𝑃 + 𝑇𝑚), with 
𝑾 = (𝑤1,𝑤2, … 𝑤𝑚,) (Gajewski, Simon & Carlson, 2008). For fixed n, the waiting time for the 
rest of the sample size is 𝜏 = ∑ 𝑤𝑖
𝑛
𝑖=𝑚+1 . 
 The prediction interval produced by this model provides a rule for stopping a trial with 
slow accrual. The researcher will specify a decision point, typically 25% or 50% larger than the 
planned accrual time T, that is,  𝑇𝑑𝑒𝑐𝑖𝑠𝑖𝑜𝑛 = 1.25𝑇 or  𝑇𝑑𝑒𝑐𝑖𝑠𝑖𝑜𝑛 = 1.5𝑇. It represents a delay 
large enough to threaten the successful completion of a study. If the 95% prediction interval lies 
entirely above the decision point, then there is sufficient justification to shut down the trial for 
poor accrual. 
 We present a new denotation in this paper for the predicted time to recruit fixed number 
of subjects, as the previous paper used simulation (Gajewski, Simon & Carlson, 2008). The 
conditional distribution of 𝜏 is 𝜏~G(𝑚 − 𝑛, 𝜃), with  𝑓(𝜏|𝜃) =
1
Γ(𝑛−𝑚)𝜃𝑛−𝑚
𝜏𝑛−𝑚−1𝑒−𝜏/𝜃. Then 
the predictive distribution of 𝜏 can be derived by integration, and we obtain:                                                          
𝑔(𝜏) =
1
(TP+𝑇𝑚)(1+
𝜏
TP+𝑇𝑚
)
nP+n (
𝜏
TP+𝑇𝑚
)n−m−1
Γ(𝑛𝑃+𝑛)
Γ(nP+m)Γ(𝑛−𝑚)
               (1) 
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Let 𝜙 =
𝜏
TP+𝑇𝑚
, then 𝜏 = 𝜙(TP + 𝑇𝑚),  
Therefore, 𝑔(𝜙)=
1
(1+𝜙)nP+n
𝜙n−m−1
Γ(𝑛𝑃+𝑛)
Γ(nP+m)Γ(𝑛−𝑚)
 .                                                                   (2) 
It is an inverted beta distribution (Johnson, Kotz & Balakrishnan, 1995), with 𝛼 = 𝑛 − 𝑚, 𝛽 =
𝑛𝑃 + 𝑚. When 𝛽 > 1, the mean of 𝜙 is 𝐸(𝜙) =
𝛼
𝛽−1
=
n−m
nP+m−1
. Then the predictive mean of 𝜏, 
can also be calculated directly as 
𝐸(𝜏) =
n−m
nP+m−1
(TP + 𝑇𝑚).                                                           (3) 
Similarly, the variance of 𝜏 can also be calculated as  
𝑉𝑎𝑟(𝜏) =
(n−m)(n+nP−1)
(nP+m−2)(nP+m−1)2
(TP + 𝑇𝑚)
2                                 (4) 
The percentile of 𝜏 can be obtained by  
𝑝(𝜏) = (TP + 𝑇𝑚)
𝑝(𝐵)
1−𝑝(𝐵)
 ,                                                               (5) 
where p(B) represents the percentile for the beta distribution 𝑏𝑒𝑡𝑎(𝑛 − 𝑚, 𝑛𝑃 + 𝑚). 
To evaluate the sensitivity and stability of the model in accrual prediction, we can also 
calculate the mean square error. Suppose the true accrual time is 𝑇𝑡𝑟𝑢𝑡ℎ, the total recruiting time 
is 𝑇𝑝 = 𝜏 + 𝑇𝑚. Then,  
 𝑀𝑆𝐸(𝑇𝑝) =
(n−m)(n+nP−1)
(nP+m−2)(nP+m−1)2
(TP + 𝑇𝑚)
2 + [
n−m
nP+m−1
(TP + 𝑇𝑚) + 𝑇𝑚 − 𝑇𝑡𝑟𝑢𝑡ℎ]
2 . (6)                      
2.2 Hierarchical extensions of the constant accrual model 
In the Bayesian accrual model (Gajewski, Simon & Carlson, 2008, 2011), the prior P 
needs to be specified by the researcher. However, in the evaluation by an ethical review 
committee, it is not practical to do prior specification for each study. In addition, in the monitor 
of accrual process, it may be too subjective for clinical researchers to choose a single value for 
the confidence level even if they are familiar with both similar previous trials and the current 
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study. Therefore, we proposed two adaptive priors for the Bayesian accrual model to make the 
choice of P more objective, as well as to avoid a poor choice of prior mean.  
2.2.1 Accelerated Prior 
 We define the accelerated prior (AP) as 
𝑃 = 1 −
𝑚
𝑛
 .                                                                 (7) 
P decreases proportional to the number of subjects recruited. In the beginning of the trial, when 
there are no subjects recruited, m is 0 and P is 1. The posterior distribution of θ relies entirely on 
the prior specification. As more accrual data is collected, the value of P will shrink. While all 
Bayesian models place less weight on the prior distribution as more data is collected, this 
particular approach accelerates the transition. When m is equal to n, P will be 0 and the posterior 
estimation of θ will only be based on collected data.  
2.2.2 Hedging Prior 
 As P represents the investigators’ confidence in the trial, it actually indicates the 
similarity of the current trial with historical information. Instead of fixing P as a single value, we 
can set a hierarchical model, specifying the prior distribution for P as uniform (0, 1). Therefore, 
we define the hedging prior (HP) as:  
 𝜋(𝜃, 𝑃|𝑛, 𝑇) =
(TP)nP
Γ(nP)
(
1
𝜃
)
𝑛𝑃+1
 𝑒−
𝑇𝑃
𝜃                                                                    (9)  
If the prior is off target, the accumulated accrual data will force the distribution of P 
downward, representing a downweighting of the strength of the prior distribution. As more data 
inconsistent with the off target prior is accumulated, the downweighting should become greater. 
The proposed hedging prior is actually a special case of modified power prior. In 
Bayesian analysis, the modified power prior provides an efficient way to incorporate and down 
weight historical data (Ibrahim and Chen 2000, Duan 2006, Neuenschwander, Brqanson and 
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Spiegelhalter 2009). In our exponential waiting time model, the modified power prior can be 
written as  
𝜋(𝜃, 𝑃|𝑛, 𝑇) = 𝐶(𝑃)𝐿(𝜃|𝑛, 𝑇)𝑃𝜋0(𝜃)𝜋(𝑃),                                    (10) 
Denote the initial prior 𝜋0(𝜃) =
1
𝜃
, which is a special inverse gamma with both shape and scale 
parameter equaling 0. Assuming the initial prior for P is 𝜋(𝑃)~beta (a,b). When both a and b 
equal to 1, 𝜋(𝑃) = 1. The researcher’s experience and opinion on the accrual is expressed as 
𝐿(𝜃|𝑛, 𝑇) = 𝜃−𝑛𝑒−𝑇/𝜃. The normalizing coefficient 𝐶(𝑃) can be obtained by  
𝐶(𝑃) =
1
∫ 𝐿(𝜃|𝑛, 𝑇)𝑃𝜋0(𝜃)𝑑𝜃
 
 
          =
1
∫ (𝜃−𝑛𝑒−𝑇/𝜃)𝑃
1
𝜃
𝑑𝜃=
∞
0
=
1
∫ (
1
𝜃
)
𝑛𝑃+1
 𝑒
−
𝑇𝑃
𝜃 𝑑𝜃
∞
0
=
1
Γ(nP)
(TP)nP
=
(TP)nP
Γ(nP)
 .                                 (11) 
 
Finally, the full expression of the prior is 
𝜋(𝜃, 𝑃|𝑛, 𝑇) = 𝐶(𝑃)𝐿(𝜃|𝑛, 𝑇)𝑃𝜋0(𝜃)𝜋(𝑃) =
(TP)nP
Γ(nP)
(
1
𝜃
)
𝑛𝑃+1
 𝑒−
𝑇𝑃
𝜃  ,               (12)      
which is exactly the same as we defined for hedging prior. Thus, the hedging prior is a special 
case of modified power prior. The hedging prior has a simple and intuitive motivation and can be 
fit using off the shelf software, such as BUGS.  
Using the hedging prior, the posterior distribution of θ and P is  
𝜋(𝜃, 𝑃|𝑛, 𝑇, 𝑚, 𝑇𝑚) ∝
(TP)nP
Γ(nP)
(
1
𝜃
)
𝑛𝑃+𝑚+1
 𝑒−
𝑇𝑃+𝑇𝑚
𝜃  , and                                      (13) 
 
𝜋(𝑃|𝑛, 𝑇, 𝑚, 𝑇𝑚) = ∫
(TP)nP
Γ(nP)
(
1
𝜃
)
𝑛𝑃+𝑚+1
 𝑒−
𝑇𝑃+𝑇𝑚
𝜃
∞
0
dθ =
(TP)nPΓ(nP+m)
Γ(nP)(𝑇𝑃+𝑇𝑚)𝑛𝑃+𝑚
 ,             (14)                    
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where m is the number of subjects that have been recruited and  𝑇𝑚 is the time since trial started, 
which remains the same as previously defined.  
3. Application in clinical trial data 
In order to evaluate the performance of the constant accrual model and the two 
hierarchical extensions, we applied the various models in three clinical studies that were 
conducted in the University of Kansas Medical Center. Each of these studies was completed 
prior to the use of our accrual model.  
For each of the three studies, the 95% credible intervals of the predicted total accrual time 
were estimated using three weak priors: a flat prior (P=0), a very weak informative prior 
(P=0.01), and a weak informative prior (P=0.1). We also considered two strong priors: P=0.5 
and P=1. Finally we used the accelerated prior and hedging prior. We evaluated the actual 
accrual data when 1/8, 1/4, or 1/2 subjects were recruited. The mean square error was calculated 
according to equation (5).  
In addition, we also evaluated whether the methods have the ability to make a correct 
decision on whether it can alert slow trials. If the accrual is truly not on time, then 𝑇𝑡𝑟𝑢𝑡ℎ >T. As 
it would be too strict to use T directly, we define a tolerance coefficient δ, which will produce a 
decision point 𝑇𝑑𝑒𝑐𝑖𝑠𝑖𝑜𝑛 = 𝛿𝑇 that can be used for decision making. We also estimated the 
probability that the predicted total accrual time is less or equal to the cut-off time, which is 
P(𝑇𝑝≤δT ). In the current study, the decision point for each trial is set to 1.25T. 
3.1 Application Study A: Colorectal Cancer Prevention  
 Study A investigates “Tailored Touchscreen Computers for Colorectal Cancer Prevention 
in Urban Core Clinics.”  In this study, the total proposed sample size is n=460, and total time for 
accrual is 16 months (487 days). In the real data, the total number of recruited subjects is 471. 
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Assuming the accrual rate is constant, the corresponding T is 561 days. The decision point (701) 
is set 25% larger than the planned accrual, that is, 𝑇𝑑𝑒𝑐𝑖𝑠𝑖𝑜𝑛=561×1.25. The total days to recruit 
471 subjects is 𝑇𝑡𝑟𝑢𝑡ℎ=610 days, which indicates that the trial is slower than planned.  
An important feature of this accrual is the lack of constancy over time (Figure 3-1A). The 
accrual is slightly below target for the first quarter of the time, and even slower as the trial 
progresses. There is a sudden surge, however, near the end of the trial, not enough to get the trial 
back on time, but sufficient to cause difficulty for all of the accrual models.  
Figure 3-2A shows the performance of each method, assuming 1/8, 1/4, and1/2 of the 
subjects are recruited. The solid line represents 𝑇𝑡𝑟𝑢𝑡ℎ, and the dotted line represents the decision 
point, 1.25T. 
When 1/8 of the data is collected (59 patients), the total accrual time is 88 days. A simple 
linear extrapolation of this value would indicate that the entire trial would take 704 (88*8) days.  
All methods provide the point estimates much larger than the planned trial duration of 561 days, 
with the weaker priors showing more pessimistic estimates than the stronger priors. Both the 
accelerated prior and the hedging prior behave similar to the stronger priors at this point. The 
distribution of P for the hedging prior is similar to a uniform distribution, with a mean of 0.446 
(versus 0.5 for a uniform) and a 95% interval from 0.027 to 0.971 (versus 0.025 to 0.975 for a 
uniform). None of the intervals lies entirely above the decision point. The predicted 95% credible 
interval for the total accrual time covers 𝑇𝑡𝑟𝑢𝑡ℎ (610) for each of the models. 
As the trial progresses, the accrual starts to slow down. When 1/4 of the data are collected 
(136 patients), the total accrual time is 201 days. A simple linear extrapolation would indicate a 
trial duration of 804 days. All of the methods provide very large point estimates, with the weaker 
priors again producing the most pessimistic estimates. The accelerated prior continues to behave 
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like a strong prior, but the hedging prior has a point estimate and a prediction interval that more 
closely approximates a weaker prior. The distribution of P for the hedging prior has shifted 
markedly, with a mean of 0.08, representing a substantial downweighting of the prior 
distribution. 
Because of a late surge in accrual, all of the methods predict the total accrual time poorly, 
though the prediction interval for the two strongest priors and the accelerated prior still include 
𝑇𝑡𝑟𝑢𝑡ℎ. None of the intervals lies entirely above the decision point, indicating (correctly) that the 
trial should continue. 
When 1/2 of the data are collected (236 patients), the total accrual time is 368 days. A 
simple extrapolation produces an estimated trial duration of 736 days, slightly better than the 
earlier prediction. All methods are similar, though the point estimates are slightly more 
pessimistic for the weaker priors and the hedging prior. All of the intervals include the decision 
point, but they all are completely above 𝑇𝑡𝑟𝑢𝑡ℎ. The accelerated prior still behaves much like one 
of the stronger priors (P=0.5), while the hedging prior behaves much like a weaker prior (P=0.1). 
The mean for the distribution of P is 0.12, not quite as extreme as earlier, but still a substantial 
downweighting of the prior distribution. The mean squared error of prediction, which represents 
overall measure of the performance of each model, is shown on the left of Figure 3-3A. The 
performance of the strong priors and the accelerated prior seem to be superior to the weak priors 
and the hedging prior.  
Figure 3-3A right shows for each model the estimated probability that the study will 
finish earlier than the decision point. Notice that the weak priors and the hedging prior are again 
much more pessimistic than the strong priors and the accelerated prior. 
3.2 Application Study B KanQuit 2 
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 KanQuit 2 is a project targeted to treat hospitalized smokers in rural parts of the state via 
telephone counseling. The proposed total sample size is 576, and T=521. Total time to finish 
recruiting is 𝑇𝑡𝑟𝑢𝑡ℎ=1171 days, about twice as long as planned. We set the decision point to 652 
(521*1.25). Figure 3-1B shows that the accrual is very slow in the beginning. The accrual rate 
speeds up slightly when the first 1/3 of the subjects are recruited.  
 Figure 3-2B shows the coverage of predicted total accrual time using each method. 
Although there is substantial variation in the location and width of the individual prediction 
intervals, it is worth noting that every single model would have recommended early termination 
of the study even only 1/8 of the data was collected.  
With 1/8 of the data is collected (72 patients in 244 days), the simple linear extrapolation 
would estimate the total completion time to be 1,952 days, more than triple of the planned 
accrual rate. The weak priors are close to this estimate. The strong priors are less pessimistic, but 
even these priors, which weight the data much less strongly than the off target prior, still are 
pessimistic enough to recommend early termination for slow accrual. The accelerated prior 
behaves much like the strong prior. The hedging prior behaves much like a weak prior. The mean 
of the distribution of P in the hedging prior is 0.004, representing an almost total rejection of the 
off target prior. The results for all models at 1/4 and 1/2 of the subjects are similar. 
Notice that the stronger priors are actually better at including 𝑇𝑡𝑟𝑢𝑡ℎ. The downward pull 
of the off target prior prevents these models from overreacting to the temporary slow accrual at 
the start of the study.  
Figure 3-3B left shows the mean squared error of prediction. The pattern is similar to 
Figure 3-3A. Figure 3-3B right shows that for this extreme study, all the models estimate the 
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probability that the study will finish earlier than the decision point to be zero, even with only 1/8 
of the accrual data available. 
3.3 Application Study C KIS III study  
 This study evaluates the efficacy of sustained release bupropion in combination with 
health education (HE) counseling for smoking cessation among urban African American light 
smokers. The study is a two-arm, double-blinded, placebo-controlled design.   
 The total proposed sample size is n=540. The proposed total time for accrual is 24 
months, with T=730 days. The decision point is 912 (1.25*730). The real time for accrual is 
𝑇𝑡𝑟𝑢𝑡ℎ=670. There is also some minor variation in accrual rates. The study was slightly slow in 
the very beginning. Then it sped up and finished earlier than expected. Overall, this study 
represents a rather small change (less than 10%), and it would be fair to characterize the prior 
distribution as just very slightly off target. 
All the methods produced similar point estimates, which is expected for a prior 
distribution that is only slightly off target. None of the methods would suggest early termination 
of the trial for poor accrual (Figure 3-2C). Note that the prediction intervals are narrower for the 
strong priors. The accelerated prior behaves much like the strong prior, but the hedging prior also 
behaves like a strong prior. The distribution of P is similar to a uniform distribution—the mean is 
0.446, 0.507, and 0.496 respectively. All of the prediction intervals cover 𝑇𝑡𝑟𝑢𝑡ℎ.  
 Figure 3-3C right shows the estimated probability that the study will finish earlier than 
the decision point by each model. Since this study was actually accruing patients slightly faster 
than planned, each of the models estimates this probability effectively at 100%. 
4. Simulation Studies 
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 Motivated by the application of the various methods in real clinical studies, a simulation 
study was designed to evaluate the robustness and performance of proposed accelerated prior and 
hedging prior, and compare them to the constant accrual model.  
 We assume that a researcher proposed to recruit 300 subjects in 3 years. Thus n equals 
300, and T is 1095 days. If the accrual is on target, the theoretical waiting time θ0 is 3.65 
days/patient recruited. We also assume that the waiting time for slow accrual θ1 is 7.31 
days/patient (off target), and for fast accrual θ2 is 1.83 days/patient (off target). The waiting times 
for all 300 subjects are simulated based on the assumption that the waiting time for each subject 
is independently distributed as exponential (θ), or piecewise exponential (θ) to reflect a non-
homogenous process.  
 Based on the different combinations of θ0 (on target accrual), θ1 (off target, slow accrual), 
θ2 (off target, fast accrual). We designed nine studies to mimic the situations commonly 
encountered in real clinical trial studies. Study 1 represents an unbiased situation, where the 
whole accrual process is on target. The waiting time for each subject is exponential with θi =θ0 (i 
is from 1 to 300). Study 2 represents a slow accrual, in which the waiting time is two times as 
long as planned, during the whole study. Study 3 is a fast accrual and the accrual time is only 
half of the proposed time.  The other six studies resemble a step wise accrual process. Study 4 
shows a situation where the accrual is slow for the first tenth of the subjects, θi =θ1 (i is from 1 to 
30). The recruitment then goes back to normal for the rest of the subjects θi =θ0 (i is from 31 to 
300). Study 5 mimics a trial that is slow at both the first and last tenth of the subjects. Study 6 is 
similar to study 2, with the exception that the slow accrual period is longer, such that the first 
quarter of the subjects is recruited slowly. Study 7 is parallel with study 3, with slow accrual for 
both first and last quarter of subjects. Study 8 represents a trial that starts with slow accrual at the 
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first quarter, goes back to normal on the second quarter, and then catches up quickly to the 
schedule during the last half of accrual, with θi =θ2 (i is from 151 to 300). Study 9 is an example 
of a trial that is on time for the first half subjects, but lags for the last half. The theoretical 
settings of the accrual process for each study are shown in Table 1 and displayed in Figure 3-4. 
Each simulation study is repeated for 1000 times. For each simulation, 𝑇𝑡𝑟𝑢𝑡ℎ is the sum of the 
waiting times, calculated as 𝑇𝑡𝑟𝑢𝑡ℎ = ∑ 𝑤𝑖
300
𝑖=1 . The 2.5%, 50%, and 97.5% quantiles of 𝑇𝑡𝑟𝑢𝑡ℎ are 
calculated from the 1000 simulated samples. In Figure 3-4, for comparison purpose, the dotted 
line represents the theoretical accrual rate if the recruitment is unbiased or on target. The vertical 
dash line shows the theoretical time (T) for which the trial should be finished. 
 For each set of simulated data, we assume the first 1/8, 1/4, 1/2, 3/4 of the data are 
known, with m=37, 75, 150, 225, respectively. The total predicted accrual time is estimated using 
conjugate inverse gamma priors and are specified as P=0, P=0.01, P=0.1, P=0.5 and P=1, as 
well as the proposed accelerated prior and hedging prior. For each method in a particular study, 
the mean squared error of total predicted time is calculated as =
1
1000
∑ 𝑀𝑆𝐸𝑗
1000
𝑗=1  , and the 
average of the relative bias for each study is calculated as 𝑅𝐵𝐼𝐴𝑆 =
1
1000
∑
?̂?−𝑇𝑡𝑟𝑢𝑡ℎ𝑗
𝑇𝑡𝑟𝑢𝑡ℎ𝑗
×1000𝑗=1
100%. The summary of 𝑀𝑆𝐸 and 𝑅𝐵𝐼𝐴𝑆 are shown in Figure 3-5 and Figure 3-6, respectively. 
We did comparison and summarized the results for all the seven methods. As we found that the 
results between P=0 and P=0.01are very similar, we exclude P=0.01 from Figure 3-5 and 3-6 for 
the purpose of better display. 
 For the first simulation study, when the whole accrual process is on target, it is not 
surprising that the informative prior with P=1 has the smallest 𝑀𝑆𝐸. The accelerated prior 
behaves very similarly to P=0.5, which is almost as good as P=1, when 1/8, 1/4, 1/2, 3/4 of the 
data are known. The hedging prior has a slightly larger 𝑀𝑆𝐸, although much better than when P 
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is very small, P=0.1 or P=0.01, or with non-informative prior (P=0). However, for a biased 
accrual (study 2 and 3), either slow or fast, informative prior P=1 has the largest 𝑀𝑆𝐸. P=0, 
P=0.01, P=0.1 and hedging prior have smaller 𝑀𝑆𝐸. The accelerated prior has an 𝑀𝑆𝐸 
comparable to the strong priors in the beginning of the trial, but have smaller MSE when 𝑚 =
3
4
𝑛.  
 When the first 10% of subjects are slow in accrual (simulation study 4), the results of 
𝑀𝑆𝐸  are similar to study 1. The strong priors produce the smallest 𝑀𝑆𝐸. The weak priors have 
much larger 𝑀𝑆𝐸 values. The 𝑀𝑆𝐸s of accelerated prior are comparable to the strong priors. The 
hedging prior suffers from the same problems as the weak priors, giving too much weight to the 
early slow accrual data. The results from study 5 (slow first and last 1/10) are very similar to 
study 4. The remaining studies 6, 7, 8 show similar results. If the initial early accrual is slow, the 
weak priors and the hedging prior give too much weight to this data. They can recover at times 
when there is sufficient accrual data beyond the initial slow accrual period (that is, at m= 150). 
The advantage of the strong priors is that they are not unduly swayed by the early slow accrual. 
The methods all behavior similarly for study 9.  
 In each of the simulation studies, we not only estimated the total accrual time 𝑇 using all 
different methods, but also calculated the 95% credible interval 𝑇0.025 and  𝑇0.975. The correct 
coverage is defined as 𝐶𝐶𝑗 = 𝐼(𝑇𝑡𝑟𝑢𝑡ℎ𝑗 ≥ 𝑇0.025) + 𝐼(𝑇𝑡𝑟𝑢𝑡ℎ𝑗 ≤ 𝑇0.975). The total percentage 
of correct coverage is 𝐶𝐶 =
1
1000
∑ 𝐶𝐶𝑗
1000
𝑗=1 × 100%. The summary of the correct coverage is 
shown in Table 2. For unbiased accrual, the coverage probabilities of all methods are around or 
higher than 95%. When the accrual is either slow or fast, P0, P0.01 and hedging prior provide 
higher coverage all the time, where informative priors (P1, P0.5, AP) fail to cover 𝑇𝑡𝑟𝑢𝑡ℎ.  
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 In contrast, the weak priors perform poorly if there are short slow accrual periods, as in 
study 4 and 5. The hedging prior has poor coverage probability early, but seems to recover with a 
larger amount of accrual data beyond the slow initial period. Study 6, with a longer period of 
slow accrual, appears to cause problems for all of the models. Study 7, with slow accrual both 
during the first quarter and last quarter of the study, no model is consistently accurate. All of the 
methods have low coverage for study 8 and 9.   
 More important, perhaps, than the percentage of coverage is the ability of the models to 
make a correct decision on the continuation of the trial. Similar as application studies in the 
previous section, we defined a cut-off time δT that can be used for decision making. If  ?̂?0.025 >
𝛿𝑇, we should stop the trial and the decision is NOGO. If  ?̂?0.025 ≤ 𝛿𝑇, the decision is GO. For 
one simulation iteration, the correct decision can be calculated as 𝐶𝐷𝑗 = 𝐼(?̂?0.025 > 𝛿𝑇) 
𝐼(𝑇𝑡𝑟𝑢𝑡ℎ𝑗 > 𝑇)+ 𝐼(?̂?0.025 ≤ 𝛿𝑇) 𝐼(𝑇𝑡𝑟𝑢𝑡ℎ𝑗 ≤ 𝑇). The percentage of the correct decisions is 
𝐶𝐷 =
1
1000
∑ 𝐶𝐷𝑗
1000
𝑗=1 × 100% . In this simulation study, δ is also set up as 1.25.  
  For the unbiased trial, all models correctly recommend continuation of the study. For the 
slow accrual trial, all models also correctly recommend stopping the trial, but the 
recommendations to stop are more likely to come early for the weak priors and the hedging prior. 
For the fast trial, all models correctly recommend continuation. 
 The time varying models provide a much more difficult challenge. Study 4 has slow 
accrual during the first tenth of the trial, but the trial still finishes earlier than the decision point. 
All of the models correctly recommend continuation of the trial when 𝑚 =
1
2
𝑛, but the weak 
priors and the hedging prior will too frequently recommend termination of the study when 𝑚 =
1
8
𝑛 and  𝑚 =
1
4
𝑛. For study 5, 25% of the decisions are incorrect with every model, but the two 
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weakest priors (P=0 and P=0.01) perform even worse at 𝑚 =
1
8
𝑛.In study 6, the weak priors 
perform slightly better at 𝑚 =
1
8
𝑛 and the strong priors perform slightly better at 𝑚 =
1
4
𝑛 and 
𝑚 =
1
2
𝑛, but the performance of all the models is mediocre. Performance is equally mediocre for 
Study 7, with slow early accrual during the first quarter and last quarter of the trial. The strong 
priors perform especially poorly here. In contrast, the weak priors perform especially poorly for 
Study 8 especially when 𝑚 <
1
2
𝑛 . The probability of correction decision in study 9 is zero for all 
methods during the first half of the trail, slightly better 𝑚 =
3
4
𝑛.  
 5. Discussion 
 Monitoring the accrual process in clinical trials is critical, as slow recruitment results in 
increasing costs, utilizing more resources, and wasting the goodwill contribution of patient 
volunteers.  
From clinical studies, we find that that all of the models perform well when the prior is 
far off target. Even when they do not predict the trial completion time accurately, they all 
recognize early that the trial is off schedule. The performance of the strong priors is a bit 
surprising, but perhaps some of this is an accidental result of the surge in accrual later on the 
studies. The accelerated prior does not appear to behave much differently than a strong prior in 
any of the studies. In contrast, the hedging prior did seem to adapt its behavior somewhat, 
behaving more like a weak prior when the accrual was substantially off target, but like a strong 
prior when the accrual was only slightly off target. One important lesson, though, is that 
variations in accrual rates can complicate the evaluation of these models.  
When there is variation in accrual rates, strong priors appear to perform better. This result 
is somewhat surprising. Placing a high weight on an off target informative prior would seem to 
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be a bad idea. Perhaps, though, the weak priors are placing too much weight on the slow early 
accrual which is not going to last throughout the trial. Overall, strong priors are likely to 
overreact to a bit of slow accrual data early in the study. But every prior, weak or strong, has 
difficulty with at least some of the time varying scenarios. 
 The simulation studies show that the informative prior, especially strong informative 
prior, works better when the accrual is on target, or slightly off from the target, producing 
smaller 𝑀𝑆𝐸, higher percentage of coverage, and more correct decisions. However, they are 
terrible when the accrual is entirely off from the target. Flat prior and weak informative prior are 
less efficient when the accrual is on target, but work well for very slow accrual.  
Performance of the accelerated prior is typically similar to the strong priors in the early 
period of trial. However, it is superior to strong priors when more data are available for off target 
accruals. The accelerated prior was designed to transition rapidly from a strong to a weak prior 
when more accrual data is available. The accelerated prior is equivalent to P=0.5 when half the 
data is collected, and this is still a strong prior distribution. It might be worth examining an even 
stronger degree of acceleration, such as a cubed acceleration, 𝑃 = (1 −
𝑚
𝑛
)
3
, which would be 
equivalent to P=0.125 when half of the data is collected.  Another alternate form of P would be 
set 𝑃 = 1 −
2𝑚
𝑛
 for m≤n/2, and P=0 for m>n/2. The degree of acceleration will be stronger than 
the accelerated prior we proposed. It has intuitive appeal, as in most trials, the halfway point may 
be considered a reasonable time to rely on the data that have been observed. 
The performance of the hedging prior is difficult to characterize well, but it appears to 
perform better than strong priors when the prior is extremely off target, but also superior to flat 
priors when the prior is on target or only slightly off target. We have shown that the hedging 
prior is equivalent to the modified power prior, but it is easier to fit. Instead of monitoring the 
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accrual process and assessment of the prior P subjectively, the hedging prior evaluates the 
similarity of real accrual process and historical data simultaneously, and adjusts the weights of 
the prior thereafter. It could be a useful compromise between the completely data driven flat 
prior and the reliance on investigator’s opinion that a strong prior offers. Hedging prior is a 
special case of modified power prior. However, it avoids an extra “missing integral step”. More 
importantly, hedging prior preserves the prior interpretation found in original constant accrual 
model.  
As the non-constant accrual rate changes over time. If we know for sure that the accrual 
can be divided into a certain number of stages and an appropriate prior can be selected for each 
specific stage. Then the strong prior will perform well in accrual prediction. However, there are 
many factors that affect the accrual process. The change time point of the accrual and its 
direction (slow or fast) is unpredictable, such as simulation study 8 and 9. It is hard to know what 
the accrual will be in certain stage and it is impossible choose the appropriate informative prior 
for each stage. Actually, there are examples of Bayesian regression models that could be adapted 
to this problem. We plan to consider some of these models in a future publication. 
Overall, there is no obvious choices among the various models proposed here. There are 
trade-offs between the greater precision provided by the strong priors and the ability of the weak 
priors to recognize more rapidly problems with slow accrual.  
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Appendix: Mathematical formulas for deriving closed form of constant exponential waiting 
time model 
Assuming that the waiting time (w) for each successive patient follows an exponential 
distribution, 𝑤𝑖~exp (𝜃), where θ represents the average accrual time for the ith subject. The 
distribution of the waiting time (w) is 𝑓(𝑤|𝜃) =
1
θ
𝑒−𝑤/𝜃.  The prior distribution of 𝜃 is assumed 
to be invers gamma, 𝜃~𝐼𝐺(𝑛𝑃, 𝑇𝑃), where P is the investigator’s confidence on the original 
plan, measured on a 0-1 scale. Supposedly during a trial, m subjects have been collected in 𝑇𝑚 
(𝑇𝑚  = ∑ 𝑤𝑖
𝑚
𝑖=1 ) time period. Then the posterior distribution for 𝜃 is updated to 𝜃|𝑤~IG(𝑛𝑃 +
𝑚, 𝑇𝑃 + 𝑇𝑚), which can also be written as: 
𝑓(𝜃|𝑚, 𝑇𝑚) =
(𝑇𝑃+𝑇𝑚)
𝑛𝑃+𝑚 
Γ(𝑛𝑃+𝑚)
𝜃−(𝑛𝑃+𝑚+1)𝑒−
𝑇𝑃+𝑇𝑚
𝜃 .                                     (1) 
For fixed n, the waiting time for the rest of the sample size is 𝜏 = ∑ 𝑤𝑖
𝑛
𝑖=𝑚+1 .  
 We present a new denotation in this paper for the predicted time to finish for fixed 
sample size, as the previous paper used simulation. The distribution of 𝜏 is 𝜏~G(𝑚 − 𝑛, 𝜃), with  
𝑓(𝜏|𝜃) =
1
Γ(𝑛−𝑚)𝜃𝑛−𝑚
𝜏𝑛−𝑚−1𝑒−𝜏/𝜃. Then the predictive distribution of 𝜏 can be derived as 
following,                                                                   
𝑔(𝜏) = ∫
(TP+𝑇𝑚)
nP+m
Γ(nP+m)
𝜃−(𝑛𝑃+𝑚+1)𝑒−(𝑇𝑃+𝑇𝑚)/𝜃
∞
0
1
Γ(𝑛−𝑚)𝜃𝑛−𝑚
𝜏𝑛−𝑚−1𝑒−𝜏/𝜃𝑑𝜃               (2) 
         =
(TP+𝑇𝑚)
nP+m𝜏𝑛−𝑚−1
Γ(nP+m)Γ(𝑛−𝑚)
Γ(𝑛𝑃+𝑛)
(TP+𝑇𝑚+𝜏)nP+n
                                                       
         =
1
(TP+𝑇𝑚)(1+
𝜏
TP+𝑇𝑚
)
nP+n (
𝜏
TP+𝑇𝑚
)n−m−1
Γ(𝑛𝑃+𝑛)
Γ(nP+m)Γ(𝑛−𝑚)
 .                                            (3) 
Let 𝜙 =
𝜏
TP+𝑇𝑚
, then 𝜏 = 𝜙(TP + 𝑇𝑚),  
Therefore, 𝑔(𝜙)=
1
(TP+𝑇𝑚)(1+
𝜏
TP+𝑇𝑚
)
nP+n (
𝜏
TP+𝑇𝑚
)n−m−1
Γ(𝑛𝑃+𝑛)
Γ(nP+m)Γ(𝑛−𝑚)
|TP + 𝑇𝑚|, 
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which can be simplified as 𝑔(𝜙)=
1
(1+𝜙)nP+n
𝜙n−m−1
Γ(𝑛𝑃+𝑛)
Γ(nP+m)Γ(𝑛−𝑚)
 .                              (4) 
It is an inverted beta distribution, with 𝛼 = 𝑛 − 𝑚, 𝛽 = 𝑛𝑃 + 𝑚. When 𝛽 > 1, the mean of 𝜙 is 
𝐸(𝜙) =
𝛼
𝛽−1
=
n−m
nP+m−1
. Then the predictive mean of 𝜏, can also be calculated directly as 
𝐸(𝜏) = 𝐸(𝜙)(TP + 𝑇𝑚) =
n−m
nP+m−1
(TP + 𝑇𝑚).                                                           (5) 
Similarly, the variance of 𝜏 can also be calculated as  
𝑉𝑎𝑟(𝜏) = 𝑉𝑎𝑟(𝜙(TP + 𝑇𝑚)) =
(n−m)(n+nP−1)
(nP+m−2)(nP+m−1)2
(TP + 𝑇𝑚)
2                                 (6) 
The percentile of 𝜏 can be obtained by  
𝑝(𝜏) = (TP + 𝑇𝑚)𝑝(𝜙) = (TP + 𝑇𝑚)
𝑝(𝐵)
1−𝑝(𝐵)
 ,                                                               (7) 
where p(B) represents the percentile for the beta distribution 𝑏𝑒𝑡𝑎(𝑛 − 𝑚, 𝑛𝑃 + 𝑚). 
To evaluate the sensitivity and stability of the model in accrual prediction, we can also 
calculate the mean square error. Suppose the true accrual time is 𝑇𝑡𝑟𝑢𝑡ℎ, the predicted total 
recruiting time is  𝑇𝑝 = 𝜏 + 𝑇𝑚. Then,  
𝑀𝑆𝐸(𝑇𝑝) = 𝑉𝑎𝑟(𝑇𝑝) + [𝐸(𝑇𝑝 − 𝑇𝑡𝑟𝑢𝑡ℎ)]
2 
         =
(n−m)(n+nP−1)
(nP+m−2)(nP+m−1)2
(TP + 𝑇𝑚)
2 + [
n−m
nP+m−1
(TP + 𝑇𝑚) + 𝑇𝑚 − 𝑇𝑡𝑟𝑢𝑡ℎ]
2.           (8) 
The probability that the total recruiting time is larger than critical cut-off can be calculated as the 
following: 
𝑃(𝑇𝑝 ≤ 𝛿𝑇) = 𝑃(𝜏 + 𝑇𝑚 ≤ 𝛿𝑇) = 𝑃(𝜏 ≤ 𝛿𝑇 − 𝑇𝑚) = 𝑃 (
𝜏
TP + 𝑇𝑚
≤
𝛿𝑇 − 𝑇𝑚
TP + 𝑇𝑚
) 
                                                                                                              = 𝑃 (𝜙 ≤
𝛿𝑇−𝑇𝑚
TP+𝑇𝑚
) .            (9)                                                                                                              
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Table 1. The design of the eight simulation studies, including short description of the study, 
parameter setup, and 2.5%, 50, and 97.5% quantile of Ttruth with 1000 iterations. 
Simulation Study  Parameter setup Ttruth  
2.5%  
Ttruth  
50%  
Ttruth  
97.5%  
1 “Unbiased”  θi =θ0 for i=1 to 300  973.2 1094.9 1213.2 
2 “Slow”  θi =θ1 for i=1 to 300  1946.5 2189.8 2426.5 
3 “Fast” θi =θ2 for i=1 to 300 486.6 547.5 606.6 
4 “Slow early 1/10”  θi =θ1 for i=1 to 30 
θi =θ0 for i=31 to 300  
1072.6 1202.6 1336.9 
5 “Slow early and last 1/10”  θi =θ1 for i=1 to 30 
θi =θ0 for i=31 to 270 
θi =θ1 for i=271 to 300 
1171.3 1312.7 1469.9 
6 “Slow early ¼”  i 1 for i=1 to 35
θi =θ0 for i=76 to 300  
1211.4 1367.8 1523.5 
7 “Slow early and last ¼”  θi =θ1 for i=1 to 75 
θi =θ0 for i=76 to 225 
θi =θ1 for i=226 to 300 
1455.0 1642.0 1831.7 
8 “ Slow early ¼ and fast last ½  θi =θ1 for i=1 to 75 
θi =θ0 for i=76 to 150 
θi =θ2 for i=151 to 300 
962.0 1091.3 1237.6 
9 “ On time first ½ and slow last ½ θi =θ0 for i=1 to 150 
θi =θ1 for i=150 to 300 
 
1451.8 1641.3 1827.9 
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 Table 3-1. The design of the eight simulation studies, including short description of the 
study, parameter setup, and 2.5%, 50, and 97.5% quantile of Ttruth with 1000 iterations. 
Simulation Study  Parameter setup Ttruth  
2.5%  
Ttruth  
50%  
Ttruth  
97.5%  
1 “Unbiased”  θi =θ0 for i=1 to 300  973.2 1094.9 1213.2 
2 “Slow”  θi =θ1 for i=1 to 300  1946.5 2189.8 2426.5 
3 “Fast” θi =θ2 for i=1 to 300 486.6 547.5 606.6 
4 “Slow early 1/10”  θi =θ1 for i=1 to 30 
θi =θ0 for i=31 to 300  
1072.6 1202.6 1336.9 
5 “Slow early and last 1/10”  θi =θ1 for i=1 to 30 
θi =θ0 for i=31 to 270 
θi =θ1 for i=271 to 300 
1171.3 1312.7 1469.9 
6 “Slow early ¼”  i 1 for i=1 to 35
θi =θ0 for i=76 to 300  
1211.4 1367.8 1523.5 
7 “Slow early and last ¼”  θi =θ1 for i=1 to 75 
θi =θ0 for i=76 to 225 
θi =θ1 for i=226 to 300 
1455.0 1642.0 1831.7 
8 “ Slow early ¼ and fast last ½  θi =θ1 for i=1 to 75 
θi =θ0 for i=76 to 150 
θi =θ2 for i=151 to 300 
962.0 1091.3 1237.6 
9 “ On time first ½ and slow last ½ θi =θ0 for i=1 to 150 
θi =θ1 for i=150 to 300 
 
1451.8 1641.3 1827.9 
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Table 3-2. Summary of the percentage of coverage of  𝑇𝑡𝑟𝑢𝑡ℎ and the percentage of correct 
decisions to either continue or stop the trial (shaded) using the various methods when 
recruited the first 1/8, 1/4 or 1/2 of the subjects in the eight simulation studies for 1000 
iterations. 
                                             
  Method
  
Unbiased Slow Fast Slow 
early 1/10 
Slow 
early and 
last 1/10 
Slow 
early ¼ 
Slow 
early and 
last ¼ 
Slow 
early ¼ 
and fast 
last ½ 
On time  
first ½ 
and lags 
last ½ 
  1 2 3 4 5 6 7 8 9 
 
 
1/8 
 
 
 
 
P0 96 95 95 8 18 10 50 0 31 
P0.01 97 94 95 9 21 13 56 0 27 
P0.1 99 60 12 19 48 40 92 1 6 
P0.5 100 0 0 65 94 95 54 5 0 
P1 99 0 0 85 97 97 10 12 0 
AP 99 0 0 82 98 98 15 10 0 
HP 100 85 78 35 59 45 74 3 1 
 
 
1/4 
 
 
 
 
P0 95 96 95 26 60 0 14 0 3 
P0.01 95 95 95 27 63 0 16 0 2 
P0.1 97 77 40 40 80 1 45 0 1 
P0.5 98 1 0 75 97 13 96 0 0 
P1 98 0 0 88 94 44 76 0 0 
AP 98 0 0 83 96 30 90 0 0 
HP 98 92 91 59 87 2 32 0 1 
 
 
1/2 
 
P0 95 95 95 61 95 6 95 0 0 
P0.01 95 94 95 62 96 8 94 0 0 
P0.1 96 88 74 70 96 12 91 0 0 
P0.5 97 19 1 85 87 40 55 0 0 
P1 97 1 0 90 78 65 22 0 0 
AP 97 19 1 85 87 40 55 0 0 
HP 96 94 94 81 91 18 89 0 0 
 
 
3/4 
 
 
 
P0 96 95 95 85 65 46 13 0 13 
P0.01 96 95 95 85 64 47 12 0 12 
P0.1 96 93 89 87 59 55 8 0 8 
P0.5 96 58 24 91 45 73 1 0 2 
P1 96 20 4 92 36 84 1 0 0 
AP 96 82 64 89 53 64 4 0 5 
HP 96 95 95 91 50 62 7 0 8 
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Table 3- 3 Summary of the percentage of correct decisions to either continue or stop 
the trial (shaded) using the various methods when recruited the first 1/8, 1/4 or 1/2 
of the subjects in the eight simulation studies for 1000 iterations. 
 
  Method
  
Unbiased Slow Fast Slow 
early 1/10 
Slow 
early and 
last 1/10 
Slow 
early ¼ 
Slow 
early and 
last ¼ 
Slow 
early ¼ 
and fast 
last ½ 
On time  
first ½ 
and lags 
last ½ 
  1 2 3 4 5 6 7 8 9 
 
 
1/8 
 
 
 
 
P0 100 88 100 31 50 58 85 15 0 
P0.01 100 86 100 35 53 60 82 18 0 
P0.1 100 61 100 61 69 67 58 40 0 
P0.5 100 8 100 97 76 58 8 94 0 
P1 100 1 100 99 75 54 2 100 0 
AP 100 2 100 99 75 54 2 99 0 
HP 100 57 100 67 70 67 55 44 0 
 
 
1/4 
 
 
 
 
P0 100 99 100 73 74 49 99 2 0 
P0.01 100 99 100 76 75 49 98 2 0 
P0.1 100 98 100 88 78 51 96 4 0 
P0.5 100 79 100 98 76 67 78 24 0 
P1 100 56 100 99 75 76 53 48 0 
AP 100 65 100 99 75 73 64 38 0 
HP 100 95 100 91 78 52 95 5 0 
 
 
1/2 
 
P0 100 100 100 97 78 67 80 20 0 
P0.01 100 100 100 97 77 67 79 21 0 
P0.1 100 100 100 98 76 72 74 27 0 
P0.5 100 100 100 99 75 81 55 47 0 
P1 100 100 100 99 75 82 41 61 0 
AP 100 100 100 99 75 81 55 47 0 
HP 100 100 100 98 76 76 69 33 0 
 
 
3/4 
 
 
 
P0 100 100 100 99 76 88 50 97 50 
P0.01 100 100 100 99 76 88 50 97 49 
P0.1 100 100 100 99 76 88 47 98 47 
P0.5 100 100 100 99 75 87 39 98 41 
P1 100 100 100 99 75 85 34 99 37 
AP 100 100 100 99 75 88 43 98 44 
HP 100 100 100 99 75 88 44 98 45 
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Figure 3-1. The accumulated accrual for application studies, A (TSCCP), B 
(KanQuit2), C (KISIII). The solid line is the real accrual. The dotted line is 
proposed reference, and the vertical dash line shows the proposed T. 
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Figure 3-2. The prediction of total accrual time for each of the studies A (cancer), B 
(KanQuit2), C (KISIII) using various methods assuming only 1/8, 1/4, and 1/2 of the 
subjects recruited. The solid line shows the true accrual time, and the dotted line 
shows the true decision line that should stop the trial.   
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Figure 3-3. The mean squared error (left) and the probability that the predicted 
accrual time is less or equal to the cut-off time (right) for each of the application 
studies: A (TSCCP), B (KanQuit2), C (KISIII), study using various methods 
assuming only 1/8, 1/4, and 1/2 of subjects recruited. (The labels in the figure of 
Probablity of Stop Trial for the KanQuit 2 and KIS III study are overlapped is 
because the results are exactly the same).  
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Figure 3-4. The graphical display of the theoretical accrual process of the eight 
studies. The solid line is the designed simulation studies, dotted line is the reference 
if the trial is on target, and the vertical dash line shows the proposed T.  
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Figure 3-5. The MSE on log scale of each simulation study using the various 
methods (P0, P0.1, P0.5, AP, HP) when recruited the first 1/8, 1/4, 1/2 or 3/4 of the 
subjects. As the results for study 9 On time early 1/2 then slow are too close, their 
labels are overlapped.  
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 Figure 3-6. The RBIAS of each simulation study using the various methods (P0, 
P0.1, P0.5, AP, HP) when recruited the first 1/8, 1/4, 1/2 or 3/4 of the subjects. As the 
results for study 9 On time early 1/2 then slow are too close, their labels are 
overlapped.  
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CHAPTER FOUR: 
 
Open Source R Code and Smart Phone Application for Bayesian Accrual Prediction 
for Interim Review of Studies  
(To be submit to Clinical Trials) 
(The references are formatted for APA style)  
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Abstract 
 
Background: Subject recruitment for medical research is challenging. Slow patient 
accrual leads delays in research. Researchers need reliable tools to manage the accrual 
rate.  
Methods: Our previously developed Bayesian method integrates researchers' experience 
on previous trials and data from the current study, providing reliable prediction on 
accrual rate for clinical studies.  
Results: In this paper, we present a friendly graphical user interface program developed 
in R which can be easily used by clinical researchers. A closed form solution for the total 
subjects that can be recruited in a fixed time is also derived and built in an Android 
system using Java, which can be used by a web browser and Smartphone carriers. 
Conclusions: This application provides a more convenient platform for estimation and 
prediction of the accrual process. 
 
Key words: Subject Accrual, Bayesian Methods, Smartphone Application, Statistical 
Software 
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1. Introduction 
 
Subject recruitment is critical and challenging in medical research. Researchers 
tend to overestimate the pool of available subjects and underestimate the time they need 
to obtain the proposed sample sizes for their research studies. This is known as the 
“Lasagna's Law” "(Lasagna et al., 1979) and “Muench's Third Law” (Bearman et al., 
1974). Studies have shown that more than 80% of clinical trial studies ran longer than 
their accrual goals (van der Wouden, et al., 2007). The delayed subjects recruitment 
and/or insufficient sample size would have serious deleterious consequences. Extending 
the recruitment time frame will lead to increased costs and usage of resources. If the 
proposed sample size is not achieved, the study may be seriously underpowered. 
Therefore, it is important for researchers to monitor the accrual all along their study.  
 A number of studies have been done to model and predict patient accrual process. 
Both Barnard (2010) and Zhang (2012) recently reviewed the prediction methods. 
Barnard (2010) summarized the current accrual models into five categories: (a) 
unconditional model, (b) conditional model, (c) Poisson model, (d) Bayesian model, and 
(e) Monte carlo simulation Markov model. Zhang (2010) further compared the Poisson 
process-based models. Among the proposed methods, both Barnard and Zhang addressed 
the Bayesian methods conducted by Gajewski (2008). In addition, the Bayesian approach 
can utilize researcher's previous experience in similar studies or clinical opinion and 
incorporate them into prior knowledge.  When actual accrual data are available, the 
predictive distribution of the accrual becomes the weighted average of the prior 
distribution and the actual observed data. As more data are collected, the weight on 
currently observed data will be increased while the weight of prior information will be 
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decreased. The method provide an objective assessment of the accrual process. If the 
predicted accrual is so slow that it threatens the promised sample size and increases the 
trial duration of a study, this monitoring will allow internal review boards (Schroen, 
2010)  to suggest mid-course corrections in the trial, such as adding additional centers to 
a multi-center study, hiring additional study coordinators to broaden the search for 
volunteers, updating the inclusion/exclusion criteria etc. On the other hand, the method 
can also prevent a researcher from overreacting to slow accrual in the beginning of the 
study. If the accrual is faster than planned, the prediction model can provide an estimated 
closure date to avoid unnecessary patient recruitment.  
 As most clinical researchers are not proficient in using the algorithm in the 
Bayesian method to do the accrual prediction, it will be convenient for them to have 
simple and easy to use interface. In this paper, we present our R accrual package, which  
only requires the researchers to input the original design information and the updated 
accrual data with simple click and point (R Development Core Team, 2012), while using 
the Bayesian prediction model calculated in the background (Gajewski, Simon and 
Carson, 2008). The design information includes total time proposed and time subjects 
proposed, which are usually required for Institutional Review Board (IRB). The proposed 
software has three major functions: (a) provide the estimate of the total number subjects 
that the trial will have recruited within the planned time frame, (b) provide the time frame 
that the trial will successfully recruit enough number of subjects, and (c) produce 
diagnostic panel plots of the actual accrual data, such as the cumulative accrual plot, the 
distribution of the accrual etc. The accrual package has been promoted on the R listserv, 
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and is ready to be used by both statisticians and clinical researchers in evaluating and 
monitoring their subject accrual. 
 In our recent study (Jiang, Simon, Mayo & Gajewski, accepted),we derived a 
closed form solution for the posterior prediction of the accrual. The duration for the 
remaining number of subjects needed to be accrued is distributed as inverse beta. The 
percentile of the duration then can be calculated using the normal approximation of beta 
distribution. We also derive a closed form solution for the posterior prediction of the 
remaining subjects that can be recruited in a fixed time, which is a negative binomial. As 
shown in the appendix, the negative binomial can be approximated using a normal 
distribution. Based on the closed form algorithm, we developed a web browser and an 
android version of the accrual calculator, which can be easily installed and used by a 
smartphone carrier. 
  
2. Example using the R accrual package 
 The R accrual package includes an example data set, three major functions 
described below, and a graphical user interface that provides menu driven access to these 
functions in R (Figure 1). The major three R functions are accrual.n, accrual.T and 
accrual.plots. The function accrual.n calculates the prediction of the number of patients 
to be recruited in fixed time. The function accrual.T predicts the time to reached targeted 
sample size. The function accrual.plots provides a panel of plots for data diagnostics. The 
accrual.gui provides an interface that the users can choose any of the three options as 
needed. We use an example of clinical trial to illustrate how to use the R package and 
interpret the results.  
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 Suppose in a clinical trial, the researcher's original proposal is to recruit 300 
patients in 3 years (36 months). Assuming that the investigator is 50% confident that the 
accrual can be done within the planned time, that is P=0.5, and that the trial has not been 
started, the estimation of total patients will be recruited in three years can be done using 
the function accrual.n,  accrual.n (n=300,T=36,P=0.5,m=0,tm=0).In addition, users can 
also choose to use the GUI window. Figure 2A shows the interface window for the users 
to estimate “How many patients will you recruit?”, which functions exactly as accrual.n. 
In this case, the “Total sample size” is 300. “Targeted finish time in months” is 36. The 
researcher can choose any confidence level (0 to 1) by using a slider or directly entering 
the confidence level in the blank directly. In the current case, the trial has not been 
started, therefore both “Subject recruited” and “Total months after started” are 0. 
Through either of the two approaches, the prediction of the accrual is shown in Figure 
2B. The white line is the estimate of the prediction, with the grey tunnel as the prediction 
intervals. The histogram of estimated total accrual in 36 months is shown on the right. 
The horizontal line indicates the target sample size. On the top left corner of the figure, 
there are input information and the summary of the results. In this example, there will be 
300 subjects recruited in 36 months, with 95% prediction interval (247, 361). It will take 
35.9, with 95% prediction interval (29.9, 43.8) months for the investigators to recruit 300 
subjects. The plots and the summary results will help the investigators and the IRBs to 
monitor and predict the progress of the clinical trial. Please be aware there maybe a slight 
difference in the results between the displayed results and what will be obtained by the 
reader using the package. This is due to the using of simulation approach in the 
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calculation. The trivial difference will not affect the interpretation of the results and the 
evaluation of the trial progress. 
 Using the R accrual package, the recruitment of the trial can be monitored all 
along the process. For example, if the trial is in progress with 75 subjects recruited in 
12.98 months, the prediction can be done as either use accrual.n function or the 
interactive R window for data input, as shown in Figure 3A. Figure 3B shows the 
corresponding accrual plot and summary of the results. If 1/4 of total sample size, that is 
75 subjects, recruited in 12.96 months, then the predicted total subjects can be recruited 
in 3 years is 241 with 95 prediction interval (210, 277). The results indicate that it is 
highly probable that the study will not be able to recruit enough subjects within the study 
time frame given the current recruitment process. The investigator should consider 
strategies to increase the accrual rate, such as adding one more study center, and 
changing the study protocols. The researchers can use this function/option throughout 
their trial. The results also help the IRBs to evaluate the progress of the study objectively. 
In addition to estimating the total number of subjects in a fixed time, the 
investigators may also be interested in estimating the time frame to finish recruiting a 
certain number of subjects. It can be done by using function accrual.T, or the second 
option (Figure 1) “How long will it take to reach the targeted sample size?”. Similarly as 
the previous example, the researcher's original proposal is to recruit 300 patients in 36 
months, and the researcher's confidence level is also 0.5. The R window interface and 
output are shown in Figure 4A and Figure 4B respectively. In Figure 4B, the summary of 
input information and output are shown on the left bottom corner. The vertical line shows 
the targeted time (36 months). As shown clearly in Figure 4B, the predicted time to finish 
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recruiting 300 subjects is 44.1 months, with 95% predicted interval (38.9, 50.3). The 
predicted accrual is much slower than planned 36 months. The results indicated that both 
the IRBs and the investigator should pay special attention to the accrual rate as discussed 
above.  
The Bayesian accrual model is based on the assumption that the distribution of 
waiting time is exponential and the rate of the accrual is constant. Violations of the 
assumption may lead to biased estimation. Therefore, it is useful to check whether data 
(w) meet the assumption and is suitable for the current method via option “Diagnostic 
Panel”. Figure 5 A shows the windows interface of this option, in which the researchers 
can load the raw time gap data through point and click. Figure 5B shows four figures that 
help to understand the data distribution. The figure on the top left is the exponential 
quantile plot, which checks whether the distribution of waiting times is exponential. The 
current plot shows that data are off from the straight line. The top right figure shows the 
histogram of the waiting times, where the red line is the theoretical exponential 
distribution. The figure of waiting time verse cumulative accrual time is shown on the 
bottom left, and the figure of total accrual verse cumulative accrual time is shown on the 
bottom right. Both of the graphs show that this trial is piecewise constant with slower 
accrual in the beginning and at the end. 
3. Using the web-based calculator and smartphone applications 
As discussed in the paper (Gajewski, Simon and Carson, 2012), the closed form 
of time frame of accrual shows to be distributed as inverse beta. As we know, we can use 
normal approximation for both of the beta distribution, which accelerate the speed of 
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calculation greatly. The normal approximation algorithm is adopted in Java and used for 
the estimations in the accrual. Our group developed a web-based accrual software using 
Java. An example of using this web calculator is shown in Figure 6. The link to the 
software can be found at http://biostat-pts.kumc.edu/velos/RPackages/Home.html. 
With the development and wide use of smartphone devices, the accrual 
smartphone application, compared to R packages or web-based application, is more 
convenient and easier to clinical researchers. Using closed form solution for Bayesian 
accrual model and normal approximation, the methods are adopted into an Android 
application using Java. Figure 8 shows the use of an Android phone in the process of 
accrual monitoring. 
4. Feedback from clinical investigators 
In order to evaluate the developed software, we demonstrated the software to 
clinical investigators at our academic medical center. They were given a single item: “I 
would recommend this software to other researchers.” There are seven response options 
for this item: 1) `Strongly disagree'; 2) `Disagree'; 3) `Somewhat disagree'; 4) `agree or 
disagree'; 5) `Somewhat agree'; 6) `Agree'; 7) `Strongly agree'. We received eight 
responders out of 16 investigators, with three researchers chose `Strongly agree', two 
researchers choosing `Agree', one choosing `Somewhat agree' and only one choosing 
`Somewhat disagree'. The mean score of the answer is 5.87, which indicates agreement 
that the software is useful and should be introduced to more investigators. 
5. Discussion 
Both the R accrual package, the web-based as well as the Smartphone application 
for patient accrual, are based on the assumption that the accrual is constant. However, as 
94 
 
we know, in the real situation, the accrual is not constant or only piecewise constant, such 
as slow in the beginning and/or in the end. Although the software is robust when the 
assumption is only slightly violated (Jiang, Simon, Mayo & Gajewski, accepted), is still 
better to check the data distribution and use it with caution when the assumptions are 
obviously violated. Future work is to continue assessing the assumptions, build models 
when needed, and translate these methods to easy to use software for monitoring of 
clinical trials. 
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Figure 4-1. The main menu of R accrual Package with three options. 
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Figure 4-2. An example of using R accrual package to calculate the number of 
patients can be recruited in the beginning of clinical trial. (A) The interactive R 
window for data input (B) The R output for summarized results and accrual plot. 
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Figure 4-3. An example of using R accrual package to calculate the number of 
patients can be recruited when 75 subjects has been recruited. (A) The interactive R 
window for data input (B) The R output for summarized results and accrual plot. 
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Figure 4-4. An example of using R accrual package to calculate the time frame to 
reach the targeted sample size when 75 subjects has been recruited. (A) The 
interactive R window for data input (B) The R output for summarized results and 
accrual plot. 
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Figure 4-5. An example of using R accrual package to check the distribution of 
accrual data (A) The interactive R window to input data (B) The R output for 
exponential quartile plot for waiting times (top left), the histogram of the individual 
waiting times (top right), waiting times verse cumulative accrual time (bottom left), 
and the number of subjects verse cumulative accrual time (bottom right) 
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Figure 4-6. An example of using accrual web based software to calculate the number 
of patients can be recruited when 1/4 of the projected subjects has been recruited. 
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Figure 4-7. An example of using accrual web based software to calculate the time 
frame to reach the targeted sample size when 1/4 of the projected subjects has been 
recruited. 
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Figure 4-8. The using of accrual Smartphone application. 
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Appendix 
Using R, the Bayesian method for simple accrual (Gajewski, 2008) can be easily done 
using simulations. To speed up the calculation, it is better to develop closed form that can 
be used in Java. Assuming the investigator planned to recruit n subjects in T days in the 
original protocol. The Bayesian model assumes that the waiting time (w) for each 
successive patient follows an exponential distribution, that is 𝑤𝑖~exp (𝜃), where θ 
represents the average accrual time for the ith subject. We also assume that distribution of 
𝜃 is inverse gamma, 𝜃~𝐼𝐺(𝑛𝑃, 𝑇𝑃), where P is the investigator’s confidence on the 
original plan on a 0-1 scale. In the process of a trial, suppose m subjects have been 
collected in 𝑇𝑚 (𝑇𝑚  = ∑ 𝑤𝑖
𝑚
𝑖=1 ) time period. The posterior distribution for 𝜃 is  
𝑓(𝜃|𝑚, 𝑇𝑚) =
(𝑇𝑃+𝑇𝑚)
𝑛𝑃+𝑚 
Γ(𝑛𝑃+𝑚)
𝜃−(𝑛𝑃+𝑚+1)𝑒−
𝑇𝑃+𝑇𝑚
𝜃                                     (1) 
For fixed T, assuming the rest of subjects can be recruited are 𝜂~𝑃𝑜𝑖(
𝑇−𝑇𝑚
𝜃
), then the 
posterior predictive distribution of η is  
𝑔(𝜂) = ∫
(𝑇𝑃+𝑇𝑚)
𝑛𝑃+𝑚 
Γ(𝑛𝑃+𝑚)
𝜃−(𝑛𝑃+𝑚+1)𝑒−
𝑇𝑃+𝑇𝑚
𝜃
∞
0
(
𝑇−𝑇𝑚
𝜃
)𝜂
𝜂!
𝑒
𝑇−𝑇𝑚
𝜃 𝑑𝜃                   (2) 
=
(𝑇𝑃+𝑇𝑚)
𝑛𝑃+𝑚(𝑇−𝑇𝑚)𝜂 
Γ(𝑛𝑃+𝑚)𝜂!
∫ 𝜃−(𝑛𝑃+𝑚+𝜂+1)𝑒
−
𝑇𝑃+𝑇
𝜃
∞
0
𝑑𝜃                                     
=
(𝑇𝑃+𝑇𝑚)
𝑛𝑃+𝑚(𝑇−𝑇𝑚)𝜂Γ(nP+m+𝜂)
(𝑇𝑃+𝑇)nP+m+𝜂Γ(𝑛𝑃+𝑚)𝜂!
                                                                      (3) 
Define, 𝑝 =
𝑇𝑃+𝑇𝑚
TP+T
, and 𝑟 = 𝑛𝑃 + 𝑚, then 𝑔(𝜂) = 𝑝𝑟(1 − 𝑝)𝜂
Γ(r+𝜂)
Γ(𝑟)𝜂!
 .         (4) 
 The above formula shows that the distribution of η is negative binomial, NG (r,p).  
When the number of successes r is large, and p is neither very small nor very large, NG 
(r,p). can be approximated with 𝑁(
𝑟(1−𝑝)
𝑝
,
𝑟(1−𝑝)
𝑝2
). For example, when n=300, T=36, 
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P=0.05, m=75. Tm=12.98, p is 0.5737037. Obviously, it is not too small or too large, and 
r is 225, which is large. Figure S1 shows the density NG (225, 0.5737037) in dots, with 
the solid line is N(167.1885, 291.4196). The graph shows that it is reasonable to use 
normal approximation in estimating of η, the rest of subjects can be recruited. Then the 
total number of subjects can be recruited in fixed T time is η +T, The calculation of 
normal quantile can be easily adopted in Java. 
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Figure 4S-1. The distribution NB (225, 0.5737037) (dotted line)  and its 
corresponding Normal distribution approximations (solid line) 
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CHAPTER FIVE: 
 
SUMMARY AND FUTURE DIRECTIONS 
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Use of indirect measurement information in the form of a prior distribution is 
becoming more popular (Berry, 2004) and makes Bayesian methods more efficient 
(Samaniego & Reneau, 1994). We applied Bayesian methods to estimate construct 
validity in patient reported outcomes and in monitoring of subjects’ accrual in clinical 
trials.  
In the study of patient reported outcomes, we developed and evaluated Bayesian 
Instrument Development (BID). In BID, the prior probablility distribution is derived from 
the knowledge of content validity. Participant data is then used to update the posterior 
distribution. To test the stability of BID, we used simulations to compare BID with 
classical instrument development procedures. The comparisons were conducted under 
three different conditions: the priors (experts) are all unbiased, the priors (experts) are all 
biased, and the priors are contaminated. Our results showed that BID performs better than 
traditional factor analysis when using a flat or “good informative” prior. The results are 
consistent with findings by Lee (1981) and Lee & Shi (2000). It also confirms Samaniego 
and Reneau’s (1994) general findings of the Bayesian and frequentist comparison: a 
Bayesian estimator is always superior to a frequentist estimator if the bias in the Bayesian 
prior is smaller than the sample standard deviation.   
In the study of patient accrual for clinical trials, we developed two hierachical 
extensions to the Bayesian constant accrual model (Gajewski, Simon & Carlson, 2008). 
In brief, the researchers’ previous experience is incorporated into the prior distribution, 
and then the accrual data are used to update to a posterior distribution for the estimation 
of accrual duration. The two new extensions we proposed are an accelerated prior and a 
hedging prior. The performance of the Bayesian constant accrual model and the extension 
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were evaluated by clinical trial data and through simulation. Overall, the results showed 
that informative priors perform well when accrual is on target or slightly off (the prior is 
unbiased or slightly biased), but are worse when accrual is off target (the prior is biased). 
The flat or weakly informative prior performs well when the prior is biased, but are less 
efficient when the prior is unbiased. As discussed by Samaniego and Reneau (1994), bias 
in the Bayesian prior should be controlled under a certain level to be more efficient. Our 
proposed hedging prior adds the similarity between the researchers’ experience and the 
current data as a “control” in the utilization of prior information. It weighs the prior 
information more heavily in the estimation of the posterior mean when the prior is 
unbiased, but less otherwise. In our study, the hedging prior performs much like the weak 
priors when we have a biased prior, but closer to the strong informative priors when we 
have an unbiased prior.  
For both methods discussed above, we developed software with a graphical user 
interface that can be easily operated by non-statisticians, most of whom are not familiar 
with Bayesian statistics. BID is based on R and WINBUGS, and the BID software has 
been demonstrated to nursing researchers. For patient accrual, the R package accrual has 
been submitted and accepted by R CRAN, and the package is ready to used. We 
demonstrated the software to clinical researchers in a medical center. The demonstration 
showed that the researchers agree that the software is useful and should be introduced to 
more investigators.  
Overall, our Bayesian statistical methods development helps decrease the cost and 
resource utilization of health care studies. Using BID, the researcher can eliminate the 
need for unnecessary continuation of data collection for larger samples as required by the 
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classical instrument development approach, which will in turn decrease the time and cost 
of the study. Monitoring accrual in clinical trials will allow the investigator and the 
interal review boards to evaluate trial progress objectively and suggest mid-course 
corrections for the trial if accrual is slower than expected, avoiding delays in trial 
progress and increases in cost. 
A few suggestions for future studies are listed as follows: 
(1) In BID, participants’ data are assumed to continuous..Many clinical 
questionnaires are in ordinal or binary form.  It is necessary to develop Ordinal 
Bayesian Instrument Development (OBID) with an item response theory model 
(Albert & Chib, 1993; Beck & Gable, 2001). 
(2)  In the study of patient reported outcomes, we assume the experts’ opinion on 
items is independent. However, the experts’ opinions on items are most likely 
correlated in real situations. Therefore, a correlated model may be more suitable 
for estimation of the content validity (Albert et al., 2012).  Each expert will have 
an individualized prior based on their prior belief. This hierarchical approach will 
make it possible for us to evaluate the effect of a single expert on the analysis and 
draw conclusions (Ansari, Jedidi, & Jagpal, 2000). 
(3) In the Bayesian constant accrual model, the accelerated prior performs just like an 
informative prior when only the first half of the data is collected. A stronger 
degree of acceleration, such as a cubed acceleration, 𝑃 = (1 −
𝑚
𝑛
)
3
, may better 
compromise between prior information and data.  
(4) Many clinical trials are conducted in different places (i.e., multi-centered). The 
current model does not include variation from different centers. In the future, we 
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can use a hierarchical model with each center having a specific prior character 
which may represent the potential subject recruitment ability of that center (Zhang 
& Long, 2012).  
(5) As previously discussed, the actual accrual processes are typically not constant, 
but piecewise constant. For example, accrual is usually slow for the first few 
subjects as there is a training period for the staff. In this case, we can use a finite 
mixture model hyper prior to better estimate the piecewise constant case 
(McLachlan & Peel, 2004). 
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